THE FOUNDATION FOR AIDS RESEARCH: Form 990, tax year 2017

View the entire original 990 at ProPublica ↗

Organization: THE FOUNDATION FOR AIDS RESEARCH (EIN 13-3163817)
Tax period: 2017-10-01 to 2018-09-30
Filed: 2019-07-02
IRS object ID: 201931839349300408
Schema version: 2017v2.3
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule C
Schedule D
Schedule F
Schedule G
Schedule I
Schedule J
Schedule M
Schedule O

Return header ReturnHeader

Field	Value	IRS element (for citing)
Return	2019-07-02T14:07:26-05:00	ReturnTs
Tax Period End	2018-09-30	TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Preparer Firm Name PreparerFirmName

Field	Value	IRS element (for citing)
Business Name Line1	GRANT THORNTON LLP	BusinessNameLine1Txt

Preparer US Address PreparerUSAddress

Field	Value	IRS element (for citing)
Address Line1	757 THIRD AVENUE 3RD FLOOR	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	100172013	ZIPCd

Field	Value	IRS element (for citing)
Return Type	990	ReturnTypeCd
Tax Period Begin	2017-10-01	TaxPeriodBeginDt

Filer Filer

Field	Value	IRS element (for citing)
EIN	133163817	EIN

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	THE FOUNDATION FOR AIDS RESEARCH	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
In Care Of	% BRADLEY JENSEN	InCareOfNm
Business Name Control	FOUN	BusinessNameControlTxt
Phone	2128061600	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	120 WALL STREET 13TH FLOOR	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	100053908	ZIPCd

Business Officer BusinessOfficerGrp

Field	Value	IRS element (for citing)
Person	BRADLEY JENSEN	PersonNm
Person Title	ASSISTANT TREAS./CFO	PersonTitleTxt
Phone	2128061703	PhoneNum
Signature	2019-07-02	SignatureDt
Discuss With Paid Preparer	Yes (true)	DiscussWithPaidPreparerInd

Preparer Person PreparerPersonGrp

Field	Value	IRS element (for citing)
Preparer Person	Scott Thompsett	PreparerPersonNm
PTIN	P00741490	PTIN
Phone	2125990100	PhoneNum

Filing Security Information FilingSecurityInformation

IP Address IPAddress

Field	Value	IRS element (for citing)
I Pv4 Address	209.220.136.124	IPv4AddressTxt

Field	Value	IRS element (for citing)
Federal Original Submission Id	26377520191835000003	FederalOriginalSubmissionId
Federal Original Submission Id	2019-07-02	FederalOriginalSubmissionIdDt
Filing License Type	P	FilingLicenseTypeCd
At Submission Creation Device Id	4C93E105D69F40EA9BA778A85C19F4333C6FBE31	AtSubmissionCreationDeviceId
At Submission Filing Device Id	7D14034AF515942D2ABE7F7E27EA16D2649DB046	AtSubmissionFilingDeviceId

Field	Value	IRS element (for citing)
Tax	2017	TaxYr
Build TS	2019-02-21 02:37:17Z	BuildTS

Form 990 IRS990

Doing Business As Name DoingBusinessAsName

Field	Value	IRS element (for citing)
Business Name Line1	Aids Research Foundation or amfAR	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Principal Officer	KEVIN FROST	PrincipalOfficerNm

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	120 WALL STREET 13TH FLOOR	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	10005	ZIPCd

Field	Value	IRS element (for citing)
Gross Receipts	$65,167,864	GrossReceiptsAmt
Group Return For Affiliates	false	GroupReturnForAffiliatesInd
Organization501c3	Yes (X)	Organization501c3Ind
Website Address	WWW.AMFAR.ORG	WebsiteAddressTxt
Type Of Organization Corp	Yes (X)	TypeOfOrganizationCorpInd
Formation	1983	FormationYr
Legal Domicile State	NY	LegalDomicileStateCd
Activity Or Mission	AMFAR IS DEDICATED TO ENDING THE GLOBAL AIDS EPIDEMIC THROUGH INNOVATIVE RESEARCH.	ActivityOrMissionDesc
Voting Members Governing Body	12	VotingMembersGoverningBodyCnt
Voting Members Independent	12	VotingMembersIndependentCnt
Total Employee	88	TotalEmployeeCnt
Total Volunteers	0	TotalVolunteersCnt
Total Gross UBI	$0	TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm	$60,801	NetUnrelatedBusTxblIncmAmt
PY Contributions Grants	$50,842,378	PYContributionsGrantsAmt
CY Contributions Grants	$42,784,390	CYContributionsGrantsAmt
PY Program Service Revenue	$0	PYProgramServiceRevenueAmt
CY Program Service Revenue	$0	CYProgramServiceRevenueAmt
PY Investment Income	$1,434,528	PYInvestmentIncomeAmt
CY Investment Income	$1,668,073	CYInvestmentIncomeAmt
PY Other Revenue	-$11,850,334	PYOtherRevenueAmt
CY Other Revenue	-$12,144,387	CYOtherRevenueAmt
PY Total Revenue	$40,426,572	PYTotalRevenueAmt
CY Total Revenue	$32,308,076	CYTotalRevenueAmt
PY Grants And Similar Paid	$12,204,275	PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid	$12,574,033	CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members	$0	PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members	$0	CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid	$11,102,574	PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid	$11,259,330	CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns	$746,863	PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns	$735,053	CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense	$5,935,707	CYTotalFundraisingExpenseAmt
PY Other Expenses	$19,193,671	PYOtherExpensesAmt
CY Other Expenses	$14,468,481	CYOtherExpensesAmt
PY Total Expenses	$43,247,383	PYTotalExpensesAmt
CY Total Expenses	$39,036,897	CYTotalExpensesAmt
PY Revenues Less Expenses	-$2,820,811	PYRevenuesLessExpensesAmt
CY Revenues Less Expenses	-$6,728,821	CYRevenuesLessExpensesAmt
Total Assets BOY	$80,221,720	TotalAssetsBOYAmt
Total Assets EOY	$69,536,136	TotalAssetsEOYAmt
Total Liabilities BOY	$20,491,474	TotalLiabilitiesBOYAmt
Total Liabilities EOY	$16,985,457	TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY	$59,730,246	NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY	$52,550,679	NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part III	Yes (X)	InfoInScheduleOPartIIIInd
Mission	THE FOUNDATION FOR AIDS RESEARCH IS AN INTERNATIONAL NOT-FOR-PROFIT ORGANIZATION INCORPORATED IN NEW YORK IN 1989. AMFAR WAS FORMED THROUGH THE UNIFICATION IN 1985 OF TWO NOT-FOR-PROFIT ORGANIZATIONS, THE AIDS MEDICAL FOUNDATION ("AMF"), INCORPORATED IN NEW YORK IN APRIL 1983, AND THE NATIONAL AIDS RESEARCH FOUNDATION, INCORPORATED IN CALIFORNIA IN AUGUST 1985. FIRST BASED IN CALIFORNIA, AMFAR TRANSFERRED ITS LEGAL DOMICILE TO NEW YORK IN 1989, USING THE INITIAL INCORPORATION DOCUMENTS OF AMF, MAKING IT AMFS LEGAL SUCCESSOR. AMFAR HAS OFFICES IN NEW YORK, NY, WASHINGTON, D.C., AND BANGKOK, THAILAND. ON MARCH 7, 2005, THE BOARD OF TRUSTEES OF THE AMERICAN FOUNDATION FOR AIDS RESEARCH APPROVED A CHANGE IN LEGAL NAME TO "THE FOUNDATION FOR AIDS RESEARCH." ON OCTOBER 18, 2005, THE NEW YORK STATE DEPARTMENT OF STATE APPROVED THIS CHANGE. IN ADDITION, THE FOUNDATION HAS SECURED APPROVAL FOR DOING BUSINESS AS (DBA) THE FOLLOWING: - AMERICAN FOUNDATION FOR AIDS RESEARCH - AMFAR - AIDS RESEARCH	MissionDesc
Significant New Program Srvc	false	SignificantNewProgramSrvcInd
Significant Change	false	SignificantChangeInd
Expense	$18,260,220	ExpenseAmt
Grant	$10,029,065	GrantAmt
Revenue	$0	RevenueAmt
Desc	RESEARCH: AMFAR SUPPORTS RESEARCH PROJECTS THAT EXPLORE NOVEL APPROACHES TO SCIENTIFICALLY SOUND BUT UNTESTED HYPOTHESES IN ALL AREAS OF RESEARCH ON HIV/AIDS, FUNDING GOAL-ORIENTED STUDIES THAT OFTEN LACK THE PRELIMINARY DATA REQUIRED FOR SUPPORT FROM TRADITIONAL GRANT MAKERS. THE FOUNDATION PLAYS A VITAL ROLE IN HIV/AIDS RESEARCH, IDENTIFYING CRITICAL GAPS IN KNOWLEDGE AND PROVIDING ESSENTIAL SEED MONEY THAT ENABLES GRANTEES AND FELLOWS TO TEST THE MERITS OF NEW CONCEPTS OR TECHNOLOGIES THAT SUBSEQUENTLY CAN BE VALIDATED THROUGH LARGE-SCALE STUDIES, SUCH AS THOSE FUNDED BY THE U.S. NATIONAL INSTITUTES OF HEALTH. FOR FURTHER DETAILS, SEE SCHEDULE O.	Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

Field	Value	IRS element (for citing)
Expense	$5,051,313	ExpenseAmt
Grant	$2,072,635	GrantAmt
Revenue	$0	RevenueAmt
Desc	TREAT ASIA: AMFARS TREAT ASIA (THERAPEUTICS RESEARCH, EDUCATION, AND AIDS TRAINING IN ASIA) PROGRAM IS A NETWORK OF HOSPITALS, CLINICS, AND RESEARCH INSTITUTIONS WORKING WITH CIVIL SOCIETY TO ENSURE THE SAFE AND EFFECTIVE DELIVERY OF TREATMENTS FOR HIV AND ITS CO-INFECTIONS TO ADULTS AND CHILDREN ACROSS THE ASIA-PACIFIC THROUGH RESEARCH, EDUCATION, AND ADVOCACY OF EVIDENCE-BASED HIV-RELATED POLICIES. THE TREAT ASIA NETWORK ENCOMPASSES 21 ADULT AND 20 PEDIATRIC SITES THROUGHOUT THE REGION, WHICH COLLABORATE ON A VARIETY OF PROJECTS. FOR FURTHER DETAILS, SEE SCHEDULE O.	Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

Field	Value	IRS element (for citing)
Expense	$4,139,558	ExpenseAmt
Grant	$0	GrantAmt
Revenue	$0	RevenueAmt
Desc	PUBLIC INFORMATION: AMFAR SEEKS TO TRANSLATE AND DISSEMINATE INFORMATION ON IMPORTANT HIV-RELATED RESEARCH, TREATMENT, PREVENTION, AND POLICY ISSUES FOR DIVERSE AUDIENCES AND TO INCREASE AWARENESS AND KNOWLEDGE OF THE PANDEMIC. AMFAR PUBLISHES A WIDE RANGE OF EDUCATIONAL MATERIALS, MAINTAINS AN INFORMATIVE WEBSITE, AND ENGAGES RESPECTED PUBLIC FIGURES, HIV/AIDS SCIENTISTS, AND POLICYMAKERS IN COMMUNICATING THE NEED FOR CONTINUED RESEARCH TO DEVELOP NEW METHODS OF PREVENTION, TREATMENT, AND, ULTIMATELY, A CURE FOR HIV. FOR FURTHER DETAILS, SEE SCHEDULE O.	Desc

Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp (2 entries)

ExpenseExpenseAmt	GrantGrantAmt	RevenueRevenueAmt	DescDesc
$2,141,014	$21,655	$0	public policy
$921,926	$450,677	$0	GMT Initiative

Field	Value	IRS element (for citing)
Total Other Prog Srvc Expense	$3,062,940	TotalOtherProgSrvcExpenseAmt
Total Other Prog Srvc Grant	$472,332	TotalOtherProgSrvcGrantAmt
Total Other Prog Srvc Revenue	$0	TotalOtherProgSrvcRevenueAmt
Total Program Service Expenses	$30,514,031	TotalProgramServiceExpensesAmt
Described In Section501c3	Yes (true)	DescribedInSection501c3Ind
Schedule B Required	Yes (true)	ScheduleBRequiredInd
Political Campaign Acty	false	PoliticalCampaignActyInd
Lobbying Activities	Yes (true)	LobbyingActivitiesInd
Subject To Proxy Tax	false	SubjectToProxyTaxInd
Donor Advised Fund	false	DonorAdvisedFundInd
Conservation Easements	false	ConservationEasementsInd
Collections Of Art	Yes (true)	CollectionsOfArtInd
Credit Counseling	false	CreditCounselingInd
Temp Or Permanent Endowments	Yes (true)	TempOrPermanentEndowmentsInd
Report Land Building Equipment	Yes (true)	ReportLandBuildingEquipmentInd
Report Investments Other Sec	false	ReportInvestmentsOtherSecInd
Report Program Related Invst	false	ReportProgramRelatedInvstInd
Report Other Assets	false	ReportOtherAssetsInd
Report Other Liabilities	Yes (true)	ReportOtherLiabilitiesInd
Include FIN48 Footnote	Yes (true)	IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt	Yes (true)	IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt	false	ConsolidatedAuditFinclStmtInd
School Operating	false	SchoolOperatingInd
Foreign Office	Yes (true)	ForeignOfficeInd
Foreign Activities	Yes (true)	ForeignActivitiesInd
More Than5000 K To Org	Yes (true)	MoreThan5000KToOrgInd
More Than5000 K To Individuals	false	MoreThan5000KToIndividualsInd
Professional Fundraising	Yes (true)	ProfessionalFundraisingInd
Fundraising Activities	Yes (true)	FundraisingActivitiesInd
Gaming Activities	false	GamingActivitiesInd
Operate Hospital	false	OperateHospitalInd
Grants To Organizations	Yes (true)	GrantsToOrganizationsInd
Grants To Individuals	false	GrantsToIndividualsInd
Schedule J Required	Yes (true)	ScheduleJRequiredInd
Tax Exempt Bonds	false	TaxExemptBondsInd
Engaged In Excess Benefit Trans	false	EngagedInExcessBenefitTransInd
PY Excess Benefit Trans	false	PYExcessBenefitTransInd
Loan Outstanding	false	LoanOutstandingInd
Grant To Related Person	false	GrantToRelatedPersonInd
Business Rln With Org Mem	false	BusinessRlnWithOrgMemInd
Business Rln With Fam Mem	false	BusinessRlnWithFamMemInd
Business Rln With Officer Ent	false	BusinessRlnWithOfficerEntInd
Deductible Non Cash Contri	Yes (true)	DeductibleNonCashContriInd
Deductible Art Contribution	false	DeductibleArtContributionInd
Terminate Operations	false	TerminateOperationsInd
Partial Liquidation	false	PartialLiquidationInd
Disregarded Entity	false	DisregardedEntityInd
Related Entity	false	RelatedEntityInd
Related Organization Ctrl Ent	false	RelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org	false	TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp	false	ActivitiesConductedPrtshpInd
Schedule O Required	Yes (true)	ScheduleORequiredInd
IRP Document	135	IRPDocumentCnt
IRP Document W2 G	0	IRPDocumentW2GCnt
Backup Wthld Compliance	Yes (true)	BackupWthldComplianceInd
Employee	88	EmployeeCnt
Employment Tax Returns Filed	Yes (true)	EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit	Yes (true)	UnrelatedBusIncmOverLimitInd
Form990 T Filed	Yes (true)	Form990TFiledInd
Foreign Financial Account	Yes (true)	ForeignFinancialAccountInd
Foreign Country	TH	ForeignCountryCd
Prohibited Tax Shelter Trans	false	ProhibitedTaxShelterTransInd
Taxable Party Notification	false	TaxablePartyNotificationInd
Nondeductible Contributions	false	NondeductibleContributionsInd
Quid Pro Quo Contributions	Yes (true)	QuidProQuoContributionsInd
Quid Pro Quo Contri Discl	Yes (true)	QuidProQuoContriDisclInd
Form8282 Property Disposed Of	false	Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct	false	RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct	false	PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services	false	IndoorTanningServicesInd
Info In Schedule O Part VI	Yes (X)	InfoInScheduleOPartVIInd
Governing Body Voting Members	12	GoverningBodyVotingMembersCnt
Independent Voting Member	12	IndependentVotingMemberCnt
Family Or Business Rln	false	FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties	false	DelegationOfMgmtDutiesInd
Change To Org Documents	false	ChangeToOrgDocumentsInd
Material Diversion Or Misuse	false	MaterialDiversionOrMisuseInd
Members Or Stockholders	false	MembersOrStockholdersInd
Election Of Board Members	false	ElectionOfBoardMembersInd
Decisions Subject To Approva	false	DecisionsSubjectToApprovaInd
Minutes Of Governing Body	Yes (true)	MinutesOfGoverningBodyInd
Minutes Of Committees	Yes (true)	MinutesOfCommitteesInd
Officer Mailing Address	false	OfficerMailingAddressInd
Local Chapters	false	LocalChaptersInd
Form990 Provided To Gvrn Body	Yes (true)	Form990ProvidedToGvrnBodyInd
Conflict Of Interest Policy	Yes (true)	ConflictOfInterestPolicyInd
Annual Disclosure Covered Prsn	Yes (true)	AnnualDisclosureCoveredPrsnInd
Regular Monitoring Enfrc	Yes (true)	RegularMonitoringEnfrcInd
Whistleblower Policy	Yes (true)	WhistleblowerPolicyInd
Document Retention Policy	Yes (true)	DocumentRetentionPolicyInd
Compensation Process CEO	Yes (true)	CompensationProcessCEOInd
Compensation Process Other	Yes (true)	CompensationProcessOtherInd
Investment In Joint Venture	false	InvestmentInJointVentureInd
States Where Copy Of Return Is Fld	AL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	FL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	GA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	HI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MD	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NJ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NM	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	PA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	RI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	SC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	TN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	UT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	VA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WV	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WI	StatesWhereCopyOfReturnIsFldCd
Own Website	Yes (X)	OwnWebsiteInd
Upon Request	Yes (X)	UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Field	Value	IRS element (for citing)
Person	BRADLEY JENSEN	PersonNm
Phone	2128061703	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	120 WALL STREET 13TH FLOOR	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	100053908	ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (40 entries)

TitleTitleTxt	Average Hours Per WeekAverageHoursPerWeekRt	Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt	Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd	OfficerOfficerInd	Reportable Comp From OrgReportableCompFromOrgAmt	Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt	Other CompensationOtherCompensationAmt	Key EmployeeKeyEmployeeInd	Highest Compensated EmployeeHighestCompensatedEmployeeInd	Former Ofcr Director TrusteeFormerOfcrDirectorTrusteeInd
Mathilde Krim PhD
Founding Chairman(Thru 1/18)	1.0	0.0	Yes (X)	Yes (X)	$0	$0	$0
Bill Roedy
Chairman of the Board	1.0	0.0	Yes (X)	Yes (X)	$0	$0	$0
Kenneth Cole Thru 218
Chairman of the Board	1.0	0.0	Yes (X)	Yes (X)	$0	$0	$0
Patricia J Matson
Vice Chairman (Thru 6/18)	1.0	0.0	Yes (X)	Yes (X)	$0	$0	$0
Donald Capoccia
Vice Chairman (AS OF 2/18)	1.0	0.0	Yes (X)	Yes (X)	$0	$0	$0
Cindy Rachofsky
Vice Chairman	1.0	0.0	Yes (X)	Yes (X)	$0	$0	$0
John C Simons Thru 218
Vice Chairman AND TREASURER	1.0	0.0	Yes (X)	Yes (X)	$0	$0	$0
Mervyn F Silverman MDMPH
Secretary (Thru 2/18)	1.0	0.0	Yes (X)	Yes (X)	$0	$0	$0
Arlen H Andelson
Secretary	1.0	0.0	Yes (X)	Yes (X)	$0	$0	$0
Michael J Klingensmith
Treasurer	1.0	0.0	Yes (X)	Yes (X)	$0	$0	$0
Harry Belafonte
Trustee (Thru 8/18)	1.0	0.0	Yes (X)		$0	$0	$0
David Bohnett
Trustee (thru of 9/18)	1.0	0.0	Yes (X)		$0	$0	$0
Zev Braun
Trustee (NON-VOTING)	1.0	0.0	Yes (X)		$0	$0	$0
Jonathan S Canno
Trustee	1.0	0.0	Yes (X)		$0	$0	$0
Jane B Eisner NON-VOTing
Trustee (Thru 2/18)	1.0	0.0	Yes (X)		$0	$0	$0
Jay Ellis
Trustee (As of 9/18)	1.0	0.0	Yes (X)		$0	$0	$0
Aileen Getty
Trustee (as of 2/18)	1.0	0.0	Yes (X)		$0	$0	$0
Regan Hofmann
Secretary (Thru 12/17)	1.0	0.0	Yes (X)		$0	$0	$0
Michele V McNeill PharmD
Trustee (NON-VOTING)	1.0	0.0	Yes (X)		$0	$0	$0
Edward Milstein
Trustee	1.0	0.0	Yes (X)		$0	$0	$0
Peter Piot
Trustee (Thru 10/17)	1.0	0.0	Yes (X)		$0	$0	$0
Vincent A Roberti
Trustee (Thru 2/18)	1.0	0.0	Yes (X)		$0	$0	$0
Raymond F Schinazi PhD
Trustee	1.0	0.0	Yes (X)		$0	$0	$0
Alan D Schwartz
Trustee (as of 2/18)	1.0	0.0	Yes (X)		$0	$0	$0
Mario Stevenson
Trustee (as of 2/18)	1.0	0.0	Yes (X)		$0	$0	$0
Diana L Taylor NON-VOTing
Trustee (Thru 12/17)	1.0	0.0	Yes (X)		$0	$0	$0
Kevin Frost
Chief Executive Officer	40.0	0.0		Yes (X)	$458,595	$0	$104,028
Bradley Jensen
Assistant Treasurer, CFO	40.0	0.0		Yes (X)	$276,038	$0	$70,093
Rowena Johnston
ASST SEC, VP, RESEARCH	40.0	0.0		Yes (X)	$203,095	$0	$31,119
Edward Donnelly
Asst Treasurer, Controller	40.0	0.0		Yes (X)	$163,157	$0	$27,291
Eric Muscatell
Vice President of Development	40.0	0.0			$218,403	$0	$32,827	Yes (X)
Annette Sohn
Vice President, TREAT Asia PGM	40.0	0.0			$235,334	$0	$24,141	Yes (X)
AnnMarie Shannahan
Vice President, Public Info.	40.0	0.0			$234,029	$0	$33,314	Yes (X)
Gregorio Millet
Vice President, Public Policy	40.0	0.0			$188,800	$0	$45,291	Yes (X)
Andrew McInness
Director, Publications	40.0	0.0			$166,993	$0	$63,731		Yes (X)
Anthony Ancona
Vice President, Human Resource	40.0	0.0			$189,243	$0	$47,564		Yes (X)
Susan Doster
Chief Technology Officer	40.0	0.0			$149,646	$0	$50,915		Yes (X)
Bennah Serfaty
Sr Director of Communications	40.0	0.0			$132,347	$0	$61,266		Yes (X)
JONATHAN KEY
DIRECTOR, PHILANTHROPY	40.0	0.0			$190,220	$0	$53,712		Yes (X)
John F Logan JD PhD
AssT. Sec., Vp & GEN COUNSEL	40.0	0.0			$109,139	$0	$14,508			Yes (X)

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	$2,915,039	TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org	$0	TotReportableCompRltdOrgAmt
Total Other Compensation	$659,800	TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K	28	IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed	Yes (true)	FormerOfcrEmployeesListedInd
Total Comp Greater Than150 K	Yes (true)	TotalCompGreaterThan150KInd
Compensation From Other Srcs	false	CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1Txt	CityContractorAddress/USAddress/CityNm	State AbbreviationContractorAddress/USAddress/StateAbbreviationCd	ZIPContractorAddress/USAddress/ZIPCd	ServicesServicesDesc	CompensationCompensationAmt
INCA INTERNATIONAL PRODUCTIONS INC
40 WORTH STREET SUITE 827	NEW YORK	NY	10013	events production	$1,041,412
AAB PRODUCTION INC
64 ALLEN ROAD 5TH FLOOR	NEW YORK	NY	10002	Events Production	$648,220
GIBSON DUNN CRUTCHER LLP
200 PARK AVENUE	NEW YORK	NY	10166	LEGAL SERVICES	$466,724
JOSH WOODS PRODUCTION
39 WEST 14TH STREET SUITE 504	NEW YORK	NY	10011	Events Production	$420,350
EIDOLON COMMUNICATIONS INC
15 MAIDEN LANE SUITE 1401	NEW YORK	NY	10038	DIRECT MAIL/CONSULT.	$256,910

Field	Value	IRS element (for citing)
Cntrct Rcvd Greater Than100 K	13	CntrctRcvdGreaterThan100KCnt
Federated Campaigns	$135,853	FederatedCampaignsAmt
Fundraising	$31,268,021	FundraisingAmt
Government Grants	$5,761,067	GovernmentGrantsAmt
All Other Contributions	$5,619,449	AllOtherContributionsAmt
Noncash Contributions	$47,725	NoncashContributionsAmt
Total Contributions	$42,784,390	TotalContributionsAmt
Total Program Service Revenue	$0	TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$1,490,107	TotalRevenueColumnAmt
Exclusion	$1,490,107	ExclusionAmt

Incm From Invest Bond Proceeds IncmFromInvestBondProceedsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Royalties Revenue RoyaltiesRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$100,565	TotalRevenueColumnAmt
Exclusion	$100,565	ExclusionAmt

Rental Income Or Loss RentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Real	$0	RealAmt
Personal	$0	PersonalAmt

Net Rental Income Or Loss NetRentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

Field	Value	IRS element (for citing)
Securities	$18,693,800	SecuritiesAmt
Other	-$1,504	OtherAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

Field	Value	IRS element (for citing)
Securities	$18,517,338	SecuritiesAmt

Gain Or Loss GainOrLossGrp

Field	Value	IRS element (for citing)
Securities	$176,462	SecuritiesAmt
Other	-$1,504	OtherAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$177,966	TotalRevenueColumnAmt
Exclusion	$177,966	ExclusionAmt

Field	Value	IRS element (for citing)
Fundraising Gross Income	$2,043,540	FundraisingGrossIncomeAmt
Contri Rpt Fundraising Event	$31,268,021	ContriRptFundraisingEventAmt
Fundraising Direct Expenses	$14,341,010	FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$12,297,470	TotalRevenueColumnAmt
Exclusion	-$12,297,470	ExclusionAmt

Field	Value	IRS element (for citing)
Gaming Gross Income	$0	GamingGrossIncomeAmt
Gaming Direct Expenses	$0	GamingDirectExpensesAmt

Net Income From Gaming NetIncomeFromGamingGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Field	Value	IRS element (for citing)
Gross Sales Of Inventory	$48,094	GrossSalesOfInventoryAmt
Cost Of Goods Sold	$1,440	CostOfGoodsSoldAmt

Net Income Or Loss NetIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$46,654	TotalRevenueColumnAmt
Exclusion	$46,654	ExclusionAmt

Other Revenue Misc OtherRevenueMiscGrp (3 entries)

DescDesc	BusinessBusinessCd	Total Revenue ColumnTotalRevenueColumnAmt	ExclusionExclusionAmt
LIST RENTALS	900099	$2,793	$2,793
STORE SALES	900099	$2,675	$2,675
MISCELLANEOUS INCOME	900099	$396	$396

Field	Value	IRS element (for citing)
Other Revenue Total	$5,864	OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$32,308,076	TotalRevenueColumnAmt
Exclusion	-$10,476,314	ExclusionAmt

Field	Value	IRS element (for citing)
Info In Schedule O Part IX	Yes (X)	InfoInScheduleOPartIXInd

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

Field	Value	IRS element (for citing)
Total	$7,978,506	TotalAmt
Program Services	$7,978,506	ProgramServicesAmt

Grants To Domestic Individuals GrantsToDomesticIndividualsGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Foreign Grants ForeignGrantsGrp

Field	Value	IRS element (for citing)
Total	$4,595,527	TotalAmt
Program Services	$4,595,527	ProgramServicesAmt

Benefits To Members BenefitsToMembersGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

Field	Value	IRS element (for citing)
Total	$2,445,008	TotalAmt
Program Services	$1,771,295	ProgramServicesAmt
Management And General	$317,839	ManagementAndGeneralAmt
Fundraising	$355,874	FundraisingAmt

Comp Disqual Persons CompDisqualPersonsGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

Field	Value	IRS element (for citing)
Total	$6,217,335	TotalAmt
Program Services	$4,222,760	ProgramServicesAmt
Management And General	$662,299	ManagementAndGeneralAmt
Fundraising	$1,332,276	FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

Field	Value	IRS element (for citing)
Total	$379,569	TotalAmt
Program Services	$254,512	ProgramServicesAmt
Management And General	$42,153	ManagementAndGeneralAmt
Fundraising	$82,904	FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

Field	Value	IRS element (for citing)
Total	$1,688,768	TotalAmt
Program Services	$1,120,358	ProgramServicesAmt
Management And General	$229,985	ManagementAndGeneralAmt
Fundraising	$338,425	FundraisingAmt

Payroll Taxes PayrollTaxesGrp

Field	Value	IRS element (for citing)
Total	$528,650	TotalAmt
Program Services	$351,702	ProgramServicesAmt
Management And General	$63,485	ManagementAndGeneralAmt
Fundraising	$113,463	FundraisingAmt

Fees For Services Management FeesForServicesManagementGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Fees For Services Legal FeesForServicesLegalGrp

Field	Value	IRS element (for citing)
Total	$1,422,075	TotalAmt
Program Services	$1,418,720	ProgramServicesAmt
Management And General	$2,586	ManagementAndGeneralAmt
Fundraising	$769	FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

Field	Value	IRS element (for citing)
Total	$198,759	TotalAmt
Management And General	$198,759	ManagementAndGeneralAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

Field	Value	IRS element (for citing)
Total	$104,808	TotalAmt
Program Services	$104,808	ProgramServicesAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	$735,053	TotalAmt
Fundraising	$735,053	FundraisingAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

Field	Value	IRS element (for citing)
Total	$307,636	TotalAmt
Management And General	$307,636	ManagementAndGeneralAmt

Fees For Services Other FeesForServicesOtherGrp

Field	Value	IRS element (for citing)
Total	$1,599,736	TotalAmt
Program Services	$887,177	ProgramServicesAmt
Management And General	$50,513	ManagementAndGeneralAmt
Fundraising	$662,046	FundraisingAmt

Advertising AdvertisingGrp

Field	Value	IRS element (for citing)
Total	$256,584	TotalAmt
Program Services	$223,512	ProgramServicesAmt
Management And General	$3,763	ManagementAndGeneralAmt
Fundraising	$29,309	FundraisingAmt

Office Expenses OfficeExpensesGrp

Field	Value	IRS element (for citing)
Total	$72,365	TotalAmt
Program Services	$46,181	ProgramServicesAmt
Management And General	$6,201	ManagementAndGeneralAmt
Fundraising	$19,983	FundraisingAmt

Information Technology InformationTechnologyGrp

Field	Value	IRS element (for citing)
Total	$239,711	TotalAmt
Program Services	$181,387	ProgramServicesAmt
Management And General	$25,172	ManagementAndGeneralAmt
Fundraising	$33,152	FundraisingAmt

Royalties RoyaltiesGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Occupancy OccupancyGrp

Field	Value	IRS element (for citing)
Total	$1,419,478	TotalAmt
Program Services	$1,041,693	ProgramServicesAmt
Management And General	$148,154	ManagementAndGeneralAmt
Fundraising	$229,631	FundraisingAmt

Travel TravelGrp

Field	Value	IRS element (for citing)
Total	$1,181,209	TotalAmt
Program Services	$505,252	ProgramServicesAmt
Management And General	$2,092	ManagementAndGeneralAmt
Fundraising	$673,865	FundraisingAmt

Pymt Travel Entrtnmnt Pub Ofcl PymtTravelEntrtnmntPubOfclGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Conferences Meetings ConferencesMeetingsGrp

Field	Value	IRS element (for citing)
Total	$661,761	TotalAmt
Program Services	$649,394	ProgramServicesAmt
Management And General	$5,115	ManagementAndGeneralAmt
Fundraising	$7,252	FundraisingAmt

Interest InterestGrp

Field	Value	IRS element (for citing)
Total	$11	TotalAmt
Management And General	$11	ManagementAndGeneralAmt

Payments To Affiliates PaymentsToAffiliatesGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Depreciation Depletion DepreciationDepletionGrp

Field	Value	IRS element (for citing)
Total	$512,694	TotalAmt
Program Services	$383,231	ProgramServicesAmt
Management And General	$54,526	ManagementAndGeneralAmt
Fundraising	$74,937	FundraisingAmt

Insurance InsuranceGrp

Field	Value	IRS element (for citing)
Total	$328,941	TotalAmt
Program Services	$245,879	ProgramServicesAmt
Management And General	$34,983	ManagementAndGeneralAmt
Fundraising	$48,079	FundraisingAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDesc	TotalTotalAmt	Program ServicesProgramServicesAmt	Management And GeneralManagementAndGeneralAmt	FundraisingFundraisingAmt
PROGRAM MATERIALS	$1,978,880	$1,978,880
PROGRAM TECHNICAL SUPPORT	$808,415	$808,415
BAD DEBT EXPENSE	$726,368	$542,949	$77,250	$106,169
POSTAGE & SHIPPING	$559,630	$322,873	$2,820	$233,937

All Other Expenses AllOtherExpensesGrp

Field	Value	IRS element (for citing)
Total	$2,089,420	TotalAmt
Program Services	$879,020	ProgramServicesAmt
Management And General	$351,817	ManagementAndGeneralAmt
Fundraising	$858,583	FundraisingAmt

Total Functional Expenses TotalFunctionalExpensesGrp

Field	Value	IRS element (for citing)
Total	$39,036,897	TotalAmt
Program Services	$30,514,031	ProgramServicesAmt
Management And General	$2,587,159	ManagementAndGeneralAmt
Fundraising	$5,935,707	FundraisingAmt

Field	Value	IRS element (for citing)
Joint Costs	Yes (X)	JointCostsInd

Total Joint Costs TotalJointCostsGrp

Field	Value	IRS element (for citing)
Total	$506,115	TotalAmt
Program Services	$166,754	ProgramServicesAmt
Fundraising	$339,361	FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

Field	Value	IRS element (for citing)
BOY	$9,608,338	BOYAmt
EOY	$5,477,346	EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

Field	Value	IRS element (for citing)
BOY	$822,496	BOYAmt
EOY	$691,606	EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$1,054,693	BOYAmt
EOY	$699,100	EOYAmt

Accounts Receivable AccountsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$7,565,297	BOYAmt
EOY	$6,388,976	EOYAmt

Receivables From Officers Etc ReceivablesFromOfficersEtcGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Rcvbl From Disqualified Prsn RcvblFromDisqualifiedPrsnGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Oth Notes Loans Receivable Net OthNotesLoansReceivableNetGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Inventories For Sale Or Use InventoriesForSaleOrUseGrp

Field	Value	IRS element (for citing)
BOY	$444,076	BOYAmt
EOY	$425,761	EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

Field	Value	IRS element (for citing)
BOY	$2,895,192	BOYAmt
EOY	$1,960,938	EOYAmt

Field	Value	IRS element (for citing)
Land Bldg Equip Cost Or Other Bss	$7,842,486	LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec	$4,920,952	LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

Field	Value	IRS element (for citing)
BOY	$3,074,500	BOYAmt
EOY	$2,921,534	EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

Field	Value	IRS element (for citing)
BOY	$53,263,236	BOYAmt
EOY	$48,872,134	EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Investments Program Related InvestmentsProgramRelatedGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Intangible Assets IntangibleAssetsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Other Assets Total OtherAssetsTotalGrp

Field	Value	IRS element (for citing)
BOY	$1,493,892	BOYAmt
EOY	$2,098,741	EOYAmt

Total Assets TotalAssetsGrp

Field	Value	IRS element (for citing)
BOY	$80,221,720	BOYAmt
EOY	$69,536,136	EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

Field	Value	IRS element (for citing)
BOY	$3,028,826	BOYAmt
EOY	$3,655,122	EOYAmt

Grants Payable GrantsPayableGrp

Field	Value	IRS element (for citing)
BOY	$3,445,162	BOYAmt
EOY	$2,768,840	EOYAmt

Deferred Revenue DeferredRevenueGrp

Field	Value	IRS element (for citing)
BOY	$11,985,013	BOYAmt
EOY	$8,596,427	EOYAmt

Tax Exempt Bond Liabilities TaxExemptBondLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Escrow Account Liability EscrowAccountLiabilityGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Loans From Officers Directors LoansFromOfficersDirectorsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Unsecured Notes Loans Payable UnsecuredNotesLoansPayableGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Other Liabilities OtherLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$2,032,473	BOYAmt
EOY	$1,965,068	EOYAmt

Total Liabilities TotalLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$20,491,474	BOYAmt
EOY	$16,985,457	EOYAmt

Field	Value	IRS element (for citing)
Organization Follows SFAS117	Yes (X)	OrganizationFollowsSFAS117Ind

Unrestricted Net Assets UnrestrictedNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$55,835,428	BOYAmt
EOY	$48,668,968	EOYAmt

Temporarily Rstr Net Assets TemporarilyRstrNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$3,526,335	BOYAmt
EOY	$3,509,128	EOYAmt

Permanently Rstr Net Assets PermanentlyRstrNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$368,483	BOYAmt
EOY	$372,583	EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$59,730,246	BOYAmt
EOY	$52,550,679	EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$80,221,720	BOYAmt
EOY	$69,536,136	EOYAmt

Field	Value	IRS element (for citing)
Reconcilation Revenue Expnss	-$6,728,821	ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst	-$450,746	NetUnrlzdGainsLossesInvstAmt
Method Of Accounting Accrual	Yes (X)	MethodOfAccountingAccrualInd
Accountant Compile Or Review	false	AccountantCompileOrReviewInd
FS Audited	Yes (true)	FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

Field	Value	IRS element (for citing)
Separate Basis Fincl Stmt	Yes (X)	SeparateBasisFinclStmtInd

Field	Value	IRS element (for citing)
Audit Committee	Yes (true)	AuditCommitteeInd
Federal Grant Audit Required	Yes (true)	FederalGrantAuditRequiredInd
Federal Grant Audit Performed	Yes (true)	FederalGrantAuditPerformedInd

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Public Organization170	Yes (X)	PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$57,556,516	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$56,251,128	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$58,810,206	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$50,842,378	CurrentTaxYearMinus1YearAmt
Current Tax Year	$42,784,390	CurrentTaxYearAmt
Total	$266,244,618	TotalAmt

Tax Rev Levied Orgnztnl Bnft170 TaxRevLeviedOrgnztnlBnft170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Govt Furn Srvc Fclts Vl170 GovtFurnSrvcFcltsVl170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$57,556,516	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$56,251,128	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$58,810,206	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$50,842,378	CurrentTaxYearMinus1YearAmt
Current Tax Year	$42,784,390	CurrentTaxYearAmt
Total	$266,244,618	TotalAmt

Field	Value	IRS element (for citing)
Substantial Contributors Tot	$2,177,368	SubstantialContributorsTotAmt
Public Support Total170	$264,067,250	PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$804,366	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$1,652,775	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$1,316,372	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$1,354,513	CurrentTaxYearMinus1YearAmt
Current Tax Year	$1,590,672	CurrentTaxYearAmt
Total	$6,718,698	TotalAmt

Unrelated Business Net Incm170 UnrelatedBusinessNetIncm170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Other Income170 OtherIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$1,693,833	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$2,103,589	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$2,246,081	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$1,819,001	CurrentTaxYearMinus1YearAmt
Current Tax Year	$2,097,498	CurrentTaxYearAmt
Total	$9,960,002	TotalAmt

Field	Value	IRS element (for citing)
Total Support	$282,923,318	TotalSupportAmt
Public Support CY170	0.93335	PublicSupportCY170Pct
Public Support PY170	0.93697	PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170	Yes (X)	ThirtyThrPctSuprtTestsCY170Ind

Schedule B IRS990ScheduleB

Schedule C IRS990ScheduleC

Field	Value	IRS element (for citing)
Total Grassroots Lobbying		TotalGrassrootsLobbyingGrp
Total Direct Lobbying		TotalDirectLobbyingGrp
Total Lobbying Expend		TotalLobbyingExpendGrp
Other Exempt Purpose Expend		OtherExemptPurposeExpendGrp
Total Exempt Purpose Expend		TotalExemptPurposeExpendGrp
Lobbying Nontaxable Amount		LobbyingNontaxableAmountGrp
Grassroots Nontaxable		GrassrootsNontaxableGrp
Tot Lbbyng Grassroot Mns Non Tx		TotLbbyngGrassrootMnsNonTxGrp
Tot Lbby Expend Mns Lbbyng Non Tx		TotLbbyExpendMnsLbbyngNonTxGrp
Volunteers	false	VolunteersInd
Paid Staff Or Management	Yes (true)	PaidStaffOrManagementInd
Media Advertisements	false	MediaAdvertisementsInd
Mailings Members	false	MailingsMembersInd
Publications Or Broadcast	false	PublicationsOrBroadcastInd
Grants Other Organizations	false	GrantsOtherOrganizationsInd
Direct Contact Legislators	false	DirectContactLegislatorsInd
Rallies Demonstrations	false	RalliesDemonstrationsInd
Other Activities	Yes (true)	OtherActivitiesInd
Other Activities	$402,465	OtherActivitiesAmt
Total Lobbying Expenditures	$402,465	TotalLobbyingExpendituresAmt
Not Described Section501c3	false	NotDescribedSection501c3Ind
Form4720 Filed4912 Tax	false	Form4720Filed4912TaxInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	LOBBYING EXPENSES	FormAndLineReferenceDesc
Explanation	PART II-B THE FOUNDATION FOR AIDS RESEARCH DEVELOPED AN ACTION AGENDA TO END AIDS THAT IDENTIFIED CRITICAL DECISIONS THAT NEED TO BE MADE TO ADVANCE EVIDENCE BASED AIDS POLICIES. WE CREATED A VARIETY OF ISSUE BRIEFS ON TOPICS SUCH AS THE POTENTIAL IMPACT OF VARIOUS BUDGET SCENARIOS ON GLOBAL HEALTH SERVICES, AND POLICY PRIORITIES TO ADDRESS THE HIV EPIDEMIC AMONG GAY MEN IN THE US. THESE ISSUE BRIEFS WERE SHARED WITH CAPITOL HILL STAFF AND MEMBERS OF THE ADMINISTRATION. AMFAR MET REGULARLY WITH STAFF TO MEMBERS OF CONGRESS AND WITH ADMINISTRATION STAFF, AND WE PROVIDED INPUT TO THE ADMINISTRATION ON DEVELOPMENT OF THE PEPFAR BLUEPRINT FOR AN AIDS FREE GENERATION. AMFAR SPONSORED SEVERAL BRIEFINGS ON CAPITOL HILL ON AIDS POLICY AND RESEARCH ISSUES. AMFAR USES THESE BRIEFINGS AS AN EDUCATIONAL TOOL. The Foundation engaged an independent consultant to engage in lobbying activities on its behalf. Fees paid to this consultant totaled $104,808 in the fiscal year ending September 30, 2018.	ExplanationTxt

Schedule D IRS990ScheduleD

Art Public Exhibition Amounts ArtPublicExhibitionAmountsGrp

Field	Value	IRS element (for citing)
Assets Included	$474,123	AssetsIncludedAmt

Field	Value	IRS element (for citing)
Held Works Art		HeldWorksArtGrp

Collection Used Other Purposes CollectionUsedOtherPurposesGrp

Field	Value	IRS element (for citing)
Collection Used Other Purposes	Yes (X)	CollectionUsedOtherPurposesInd
Other Purposes	Donated Items, Inventory etc.	OtherPurposesDesc

Field	Value	IRS element (for citing)
Solicited Assets Sale	Yes (true)	SolicitedAssetsSaleInd

CY Endwmt Fund CYEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$593,133	BeginningYearBalanceAmt
Contributions	$4,100	ContributionsAmt
Investment Earnings Or Losses	$86,877	InvestmentEarningsOrLossesAmt
End Year Balance	$684,110	EndYearBalanceAmt

CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$541,231	BeginningYearBalanceAmt
Contributions	$5,950	ContributionsAmt
Investment Earnings Or Losses	$45,952	InvestmentEarningsOrLossesAmt
End Year Balance	$593,133	EndYearBalanceAmt

CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$493,036	BeginningYearBalanceAmt
Contributions	$7,293	ContributionsAmt
Investment Earnings Or Losses	$40,902	InvestmentEarningsOrLossesAmt
End Year Balance	$541,231	EndYearBalanceAmt

CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$490,979	BeginningYearBalanceAmt
Contributions	$7,998	ContributionsAmt
Investment Earnings Or Losses	-$5,941	InvestmentEarningsOrLossesAmt
End Year Balance	$493,036	EndYearBalanceAmt

CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$443,886	BeginningYearBalanceAmt
Contributions	$6,543	ContributionsAmt
Investment Earnings Or Losses	$40,550	InvestmentEarningsOrLossesAmt
End Year Balance	$490,979	EndYearBalanceAmt

Field	Value	IRS element (for citing)
Prmnnt Endowment Balance EOY	0.54460	PrmnntEndowmentBalanceEOYPct
Term Endowment Balance EOY	0.45540	TermEndowmentBalanceEOYPct
Endowments Held Unrelated Org	false	EndowmentsHeldUnrelatedOrgInd
Endowments Held Related Org	false	EndowmentsHeldRelatedOrgInd
Land		LandGrp
Buildings		BuildingsGrp

Leasehold Improvements LeaseholdImprovementsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$2,542,490	OtherCostOrOtherBasisAmt
Depreciation	$145,208	DepreciationAmt
Book Value	$2,397,282	BookValueAmt

Equipment EquipmentGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$304,826	OtherCostOrOtherBasisAmt
Depreciation	$266,627	DepreciationAmt
Book Value	$38,199	BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$4,995,170	OtherCostOrOtherBasisAmt
Depreciation	$4,509,117	DepreciationAmt
Book Value	$486,053	BookValueAmt

Field	Value	IRS element (for citing)
Total Book Value Land Buildings	$2,921,534	TotalBookValueLandBuildingsAmt
Federal Income Tax Liability	$0	FederalIncomeTaxLiabilityAmt

Other Liabilities Org OtherLiabilitiesOrgGrp (2 entries)

DescDesc	AmtAmt
LONG TERM LEASE LIABILITY	$1,693,649
SECTION 457 RETIREMENT LIABILITY	$271,419

Field	Value	IRS element (for citing)
Total Liability	$1,965,068	TotalLiabilityAmt
Footnote Text	Yes (X)	FootnoteTextInd
Total Rev Etc Audited Fincl Stmt	$31,971,417	TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst	-$450,746	NetUnrealizedGainsInvstAmt
Donated Services And Use Fclts	$115,591	DonatedServicesAndUseFcltsAmt
Other Revenue	-$1,504	OtherRevenueAmt
Revenue Not Reported	-$336,659	RevenueNotReportedAmt
Revenue Subtotal	$32,308,076	RevenueSubtotalAmt
Total Revenue Per Form990	$32,308,076	TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt	$39,150,984	TotExpnsEtcAuditedFinclStmtAmt
Donated Services Use Fclts	$115,591	DonatedServicesUseFcltsAmt
Other Expenses Included	-$1,504	OtherExpensesIncludedAmt
Expenses Not Reported	$114,087	ExpensesNotReportedAmt
Expenses Subtotal	$39,036,897	ExpensesSubtotalAmt
Total Expenses Per Form990	$39,036,897	TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail (3 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
ENDOWMENTS	PART V, LINE 4 AMFAR'S ENDOWMENT FUND IS INTENDED TO FUND THE VARIOUS GENERAL RESEARCH PROGRAMS THE ORGANIZATION SPONSORS. Reconciliation of Revenue & Expenses Part XI & Part XII, Line 2d Loss/Gain on Disposal of Fixed Assets $-1,504
FIN 48 - INCOME TAXES	AMFAR FOLLOWS GUIDANCE THAT CLARIFIES THE ACCOUNTING FOR UNCERTAINTY IN TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN, INCLUDING ISSUES RELATING TO FINANCIAL STATEMENT RECOGNITION AND GUIDANCE ON MEASUREMENT. THIS GUIDANCE PROVIDES THAT THE TAX EFFECTS FROM AN UNCERTAIN TAX POSITION CAN ONLY BE RECOGNIZED IN THE FINANCIAL STATEMENTS IF THE POSITION IS "MORE-LIKELY-THAN-NOT" TO BE SUSTAINED IF THE POSITION WERE TO BE CHALLENGED BY A TAXING AUTHORITY. THE ASSESSMENT OF THE TAX POSITION IS BASED SOLELY ON THE TECHNICAL MERITS OF THE POSITION, WITHOUT REGARD TO THE LIKELIHOOD THAT THE TAX POSITION MAY BE CHALLENGED. AMFAR IS EXEMPT FROM FEDERAL INCOME TAX UNDER IRC SECTION 501(C)(3), THOUGH IT IS SUBJECT TO TAX ON INCOME UNRELATED TO ITS EXEMPT PURPOSE, UNLESS THAT INCOME IS OTHERWISE EXCLUDED BY THE CODE. AMFAR HAS PROCESSES PRESENTLY IN PLACE TO ENSURE THE MAINTENANCE OF ITS TAX-EXEMPT STATUS; TO IDENTIFY AND REPORT UNRELATED INCOME; TO DETERMINE ITS FILING AND TAX OBLIGATIONS IN JURISDICTIONS FOR WHICH IT WAS NEXUS; AND TO IDENTIFY AND EVALUATE OTHER MATTERS THAT MAY BE CONSIDERED TAX POSITIONS. AMFAR HAS DETERMINED THAT THERE ARE NO MATERIAL UNCERTAIN TAX POSITIONS THAT REQUIRE RECOGNITION OR DISCLOSURE IN THE FINANCIAL STATEMENTS.
COLLECTIONS OF ART, HISTORICAL TREASURES, OR OTHER SIMILAR ASSETS	PART III, LINE 4 AMFAR HOLDS VARIOUS ITEMS OF JEWELRY, PHOTOGRAPHS AND OTHER ITEMS OF ARTISTIC VALUE THAT HAVE BEEN DONATED TO THE ORGANIZATION FOR SALE AT SPECIAL EVENTS. THE ORGANIZATION HAS MAINTAINED THESE ITEMS IN INVENTORY FOR A FEW YEARS AND IS IN THE PROCESS OF SELLING THEM.

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (true)	GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (10 entries)

RegionRegionTxt	Type Of Activities ConductedTypeOfActivitiesConductedTxt	Specific Services ProvidedSpecificServicesProvidedTxt	Region Total ExpendituresRegionTotalExpendituresAmt	OfficesOfficesCnt	EmployeeEmployeeCnt
East Asia and the Pacific	Grantmaking	n/a	$2,543,870
Europe (Including Iceland and Greenland)	Grantmaking	N/A	$1,646,178
North America	Grantmaking	N/A	$103,578
South America	Grantmaking	N/A	$144,717
South Asia	Grantmaking	N/A	$93,219
Sub-Saharan Africa	Grantmaking	N/A	$63,965
East Asia and the Pacific	Program Services	THERAPEUTICS,TRAINING	$1,827,595	1	16
East Asia and the Pacific	Fundraising	N/A	$1,853,009
Europe (Including Iceland and Greenland)	Fundraising	N/A	$7,537,495
South America	Fundraising	N/A	$518,164

Field	Value	IRS element (for citing)
Subtotal Offices	1	SubtotalOfficesCnt
Subtotal Employees	16	SubtotalEmployeesCnt
Total Office	1	TotalOfficeCnt
Total Employee	16	TotalEmployeeCnt
Subtotal Spent	$16,331,790	SubtotalSpentAmt
Total Spent	$16,331,790	TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (90 entries)

RegionRegionTxt	Purpose Of GrantPurposeOfGrantTxt	Cash GrantCashGrantAmt	Manner Of Cash DisbursementMannerOfCashDisbursementTxt	Non Cash AssistanceNonCashAssistanceAmt
East Asia/Pacific	BASIC RESEARCH	$499,920	wire transfe	$0
East Asia/Pacific	BASIC RESEARCH	$74,986	wire transfe	$0
East Asia/Pacific	GMT INITIATIVE	$184,615	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$5,254	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$6,445	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$11,906	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$9,304	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$17,273	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$62,499	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$6,250	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$9,126	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$19,996	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$17,650	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$14,600	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$9,454	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$21,224	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$16,800	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$21,328	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$22,724	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$22,464	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$21,414	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$23,630	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$21,614	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$21,446	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$14,050	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$23,200	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$20,994	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$21,256	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$61,320	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$69,357	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$7,500	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$6,825	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$6,225	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$6,600	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$7,500	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$7,500	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$7,500	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$7,500	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$7,500	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$284,731	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$184,408	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$68,602	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$7,500	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$15,000	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$15,000	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$15,000	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$15,000	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$25,000	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$20,000	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$10,046	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$10,958	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$11,351	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$6,167	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$7,690	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$13,770	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$110,962	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$15,082	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$11,658	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$9,480	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$20,740	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$13,272	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$7,939	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$86,459	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$15,194	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$6,641	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$18,750	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$5,625	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$5,625	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$5,625	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$5,625	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$5,625	wire transfe	$0
East Asia/Pacific	TREAT ASIA	$15,000	wire transfe	$0
Europe	BASIC RESEARCH	$75,000	wire transfe	$0
Europe	BASIC RESEARCH	$289,933	wire transfe	$0
Europe	BASIC RESEARCH	$270,025	wire transfe	$0
Europe	BASIC RESEARCH	$6,667	wire transfe	$0
Europe	RESEARCH	$129,113	wire transfe	$0
Europe	RESEARCH	$680,440	wire transfe	$0
Europe	RESEARCH	$195,000	wire transfe	$0
North America (excl USA)	BASIC RESEARCH	$33,334	wire transfe	$0
North America (excl USA)	BASIC RESEARCH	$75,000	wire transfe	$0
South America	BASIC RESEARCH	$15,000	wire transfe	$0
South America	GMT INITIATIVE	$150,288	wire transfe	$0
South Asia	PUBLIC POLICY	$24,989	wire transfe	$0
South Asia	TREAT ASIA	$7,500	wire transfe	$0
South Asia	TREAT ASIA	$15,776	wire transfe	$0
South Asia	TREAT ASIA	$11,250	wire transfe	$0
South Asia	TREAT ASIA	$15,000	wire transfe	$0
South Asia	TREAT ASIA	$8,704	wire transfe	$0
Sub-Saharan Africa	TREAT ASIA	$63,965	WIRE TRANSFE	$0

Field	Value	IRS element (for citing)
Total501c3 Org	90	Total501c3OrgCnt
Transfer To Foreign Corp	false	TransferToForeignCorpInd
Interest In Foreign Trust	false	InterestInForeignTrustInd
Foreign Corp Ownership	false	ForeignCorpOwnershipInd
Passive Foreign Investmest Co	false	PassiveForeignInvestmestCoInd
Foreign Partnership	false	ForeignPartnershipInd
Boycott Countries	false	BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (3 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
FOREIGN ACTIVITIES	PART I, LINE 2 INTERNATIONAL ORGANIZATIONS ARE RECOMMENDED FOR FUNDING BASED UPON THE RESULTS OF COMMUNITY-BASED PEER REVIEW AND/OR PROGRAM STAFF ASSESSMENT OF PROPOSAL MERIT AND ORGANIZATION CAPACITY TO UNDERTAKE PROPOSED PROJECTS THAT ARE CHARITABLE IN PURPOSE. PRE-AWARD DUE-DILIGENCE FOR NEW INTERNATIONAL GRANTEES INCLUDES REVIEW OF ORGANIZATION DOCUMENTS AND REGISTRATIONS TO VERIFY THAT THE ORGANIZATION OPERATES FOR A CHARITABLE PURPOSE AND THAT BASIC CAPACITY FOR PROJECT OVERSIGHT AND GOVERNANCE HAS BEEN ESTABLISHED. ALL INTERNATIONAL GRANTEES ARE REQUIRED TO REPORT SEMI-ANNUALLY ON PROJECT PROGRESS AND EXPENDITURES; CONTINUED REPORTING IS REQUIRED UNTIL SUCH TIME AS GRANT FUNDS ARE EXPENDED IN FULL. REPORTS ARE REVIEWED BY ADMINISTRATIVE AND PROGRAM STAFF. ADDITIONAL OVERSIGHT IS PROVIDED AS NECESSARY BY MEANS OF ONGOING, INFORMAL CONTACT WITH SITES REGARDING PROGRESS AND TECHNICAL ISSUES AND SITE VISITS WHERE FEASIBLE. INTERNATIONAL RESEARCH GRANT RECIPIENTS SUBMIT AN INTERIM AND A FINAL PROGRESS REPORTING ADDITION TO EXPENDITURES REPORTS DUE FOLLOWING THE ENDS OF THE 2ND, 3RD AND FINAL QUARTERS OF THE PERFORMANCE PERIOD.
FOREIGN ACTIVITIES	PART I, LINE 3, COLUMN D THE FOUNDATION FOR AIDS RESEARCH CONDUCTS MANY OF ITS GRANT-MAKING PROGRAM SERVICES (SEE PART III OF FORM 990) IN U.S. AND FOREIGN JURISDICTIONS. IN COLUMN D, THE ORGANIZATION HAS REPORTED THE BASIC PROGRAM THESE GRANTS SUPPORT; PLEASE REFER TO PART III FOR MORE INFORMATION ABOUT THESE PROGRAMS/INITIATIVES.
FOREIGN ACTIVITIES - STATUS OF GRANTEES	THE FOUNDATION FOR AIDS RESEARCH SUPPORTS MANY NON-U.S. ORGANIZATIONS IN THE FIGHT AGAINST AIDS AND HIV-RELATED DISEASES. FOR PURPOSES OF SCHEDULE F, PART II, LINE 2 - ALL 90 CHARITIES SUPPORTED ARE PRESUMED TO BE THE EQUIVALENT OF U.S. CHARITIES.

Schedule G IRS990ScheduleG

Field	Value	IRS element (for citing)
Mail Solicitations	Yes (X)	MailSolicitationsInd
Email Solicitations	Yes (X)	EmailSolicitationsInd
Phone Solicitations	Yes (X)	PhoneSolicitationsInd
Solicitation Of Non Govt Grants	Yes (X)	SolicitationOfNonGovtGrantsInd
Solicitation Of Govt Grants	Yes (X)	SolicitationOfGovtGrantsInd
Special Fundraising Events	Yes (X)	SpecialFundraisingEventsInd
Agrmt Prof Fundraising Acty	Yes (true)	AgrmtProfFundraisingActyInd

Fundraiser Activity Info FundraiserActivityInfoGrp (4 entries)

ActivityActivityTxt	Fundraiser Control Of FundsFundraiserControlOfFundsInd	Gross ReceiptsGrossReceiptsAmt	Retained By ContractorRetainedByContractorAmt	Net To OrganizationNetToOrganizationAmt
aab productions INC
events production	false	$24,583,369	$682,268	$23,901,102
EIDOLON COMM INC
direct mail	false	$1,934,251	$286,181	$1,648,070
Donor Services Group LLC
Tele marketing	false	$0	$1,829	-$1,829
Josh Woods Production
events Production	false	$4,164,907	$345,000	$3,819,907

Field	Value	IRS element (for citing)
Total Gross Receipts	$30,682,527	TotalGrossReceiptsAmt
Total Retained By Contractors	$1,315,278	TotalRetainedByContractorsAmt
Total Net To Organization	$29,367,250	TotalNetToOrganizationAmt
Licensed States	AL	LicensedStatesCd
Licensed States	AK	LicensedStatesCd
Licensed States	AR	LicensedStatesCd
Licensed States	CA	LicensedStatesCd
Licensed States	CO	LicensedStatesCd
Licensed States	CT	LicensedStatesCd
Licensed States	DC	LicensedStatesCd
Licensed States	FL	LicensedStatesCd
Licensed States	GA	LicensedStatesCd
Licensed States	HI	LicensedStatesCd
Licensed States	IL	LicensedStatesCd
Licensed States	KS	LicensedStatesCd
Licensed States	KY	LicensedStatesCd
Licensed States	LA	LicensedStatesCd
Licensed States	ME	LicensedStatesCd
Licensed States	MD	LicensedStatesCd
Licensed States	MA	LicensedStatesCd
Licensed States	MI	LicensedStatesCd
Licensed States	MN	LicensedStatesCd
Licensed States	MS	LicensedStatesCd
Licensed States	MO	LicensedStatesCd
Licensed States	NV	LicensedStatesCd
Licensed States	NH	LicensedStatesCd
Licensed States	NJ	LicensedStatesCd
Licensed States	NM	LicensedStatesCd
Licensed States	NY	LicensedStatesCd
Licensed States	NC	LicensedStatesCd
Licensed States	ND	LicensedStatesCd
Licensed States	OH	LicensedStatesCd
Licensed States	OK	LicensedStatesCd
Licensed States	OR	LicensedStatesCd
Licensed States	PA	LicensedStatesCd
Licensed States	RI	LicensedStatesCd
Licensed States	SC	LicensedStatesCd
Licensed States	TN	LicensedStatesCd
Licensed States	TX	LicensedStatesCd
Licensed States	UT	LicensedStatesCd
Licensed States	VA	LicensedStatesCd
Licensed States	WA	LicensedStatesCd
Licensed States	WV	LicensedStatesCd
Licensed States	WI	LicensedStatesCd

Fundraising Event Information FundraisingEventInformationGrp

Field	Value	IRS element (for citing)
Event1	Cannes	Event1Nm
Gross Receipts Event1	$12,592,424	GrossReceiptsEvent1Amt
Charitable Contri Event1	$12,169,924	CharitableContriEvent1Amt
Gross Revenue Event1	$422,500	GrossRevenueEvent1Amt
Rent Facility Costs Event1	$1,313,249	RentFacilityCostsEvent1Amt
Food And Beverage Event1	$407,894	FoodAndBeverageEvent1Amt
Entertainment Event1	$1,816,828	EntertainmentEvent1Amt
Other Direct Expenses Event1	$2,908,726	OtherDirectExpensesEvent1Amt
Event2	Dallas	Event2Nm
Gross Receipts Event2	$3,879,548	GrossReceiptsEvent2Amt
Charitable Contri Event2	$3,677,858	CharitableContriEvent2Amt
Gross Revenue Event2	$201,690	GrossRevenueEvent2Amt
Rent Facility Costs Event2	$277,433	RentFacilityCostsEvent2Amt
Food And Beverage Event2	$213,512	FoodAndBeverageEvent2Amt
Entertainment Event2	$18,019	EntertainmentEvent2Amt
Other Direct Expenses Event2	$545,286	OtherDirectExpensesEvent2Amt
Other Events Total	24	OtherEventsTotalCnt
Gross Receipts Other Events	$16,669,851	GrossReceiptsOtherEventsAmt
Charitable Contri Other Events	$15,250,501	CharitableContriOtherEventsAmt
Gross Revenue Other Events	$1,419,350	GrossRevenueOtherEventsAmt
Rent Fclty Costs Other Events	$1,031,298	RentFcltyCostsOtherEventsAmt
Food And Beverage Other Events	$926,491	FoodAndBeverageOtherEventsAmt
Entertainment Other Events	$1,844,078	EntertainmentOtherEventsAmt
Oth Direct Expnss Other Events	$3,038,196	OthDirectExpnssOtherEventsAmt
Gross Receipts Total	$33,141,823	GrossReceiptsTotalAmt
Charitable Contributions Tot	$31,098,283	CharitableContributionsTotAmt
Gross Revenue Total Events	$2,043,540	GrossRevenueTotalEventsAmt
Rent Fclty Costs Total Events	$2,621,980	RentFcltyCostsTotalEventsAmt
Food And Beverage Total Events	$1,547,897	FoodAndBeverageTotalEventsAmt
Entertainment Total Events	$3,678,925	EntertainmentTotalEventsAmt
Oth Direct Expnss Total Events	$6,492,208	OthDirectExpnssTotalEventsAmt
Direct Expense Summary Events	$14,341,010	DirectExpenseSummaryEventsAmt
Net Income Summary	-$12,297,470	NetIncomeSummaryAmt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	SCHEDULE G, PART I	FormAndLineReferenceDesc
Explanation	THE FOUNDATION FOR AIDS RESEARCH ACTUALLY PAID OUT $735,053 IN FUNDRAISING EXPENSES FOR THE YEAR ENDING SEPTEMBER 30, 2018. THIS AMOUNT IS REPORTED ON PART IX, LINE 11(E). FOR PURPOSES OF SCHEDULE G, THE FOUNDATION IS REPORTING ALL AMOUNTS PAID TO THE CONSULTANTS LISTED ON PART I, REGARDLESS OF WHETHER SUCH AMOUNTS WERE PURE FUNDRAISING EXPENSES OR EVENT PRODUCTION COSTS. ON SCHEDULE G, THE TOTAL AMOUNT PAID TO THE ORGANIZATIONS LISTED IS $1,315,278. OF THAT $1,315,278, ONLY $735,053 WAS PAID FOR FUNDRAISING SERVICES, THE REMAINING $580,225 WAS PAID FOR EVENT PRODUCTION SERVICES. IN THE INTERESTS OF CLARITY, THE FOUNDATION WOULD ALSO LIKE TO MAKE CLEAR THAT THE COMPENSATION REPORTED AS HAVING BEEN PAID TO THE PROFESSIONAL FUNDRAISERS REPORTED ON SCHEDULE G IS REPORTED ON A FISCAL YEAR BASIS. SOME OF THOSE SAME FUNDRAISERS ARE REPORTED ON THE FOUNDATION'S TOP 5 HIGHEST PAID INDEPENDENT CONTRACTORS LIST (IN SCHEDULE O). IN COMPLIANCE WITH THE INSTRUCTIONS TO THE FORM 990, COMPENSATION REPORTED FOR PART VII (AND LISTED IN SCHEDULE O) IS REPORTED ON A CALENDAR YEAR BASIS. ACCORDINGLY, AMOUNTS ON PART VII AND SCHEDULE G WILL NOT RECONCILE.	ExplanationTxt

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (true)	GrantRecordsMaintainedInd

Recipient Table RecipientTable (42 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	Recipient EINRecipientEIN	IRC SectionIRCSectionDesc	Cash GrantCashGrantAmt	Non Cash AssistanceNonCashAssistanceAmt	Purpose Of GrantPurposeOfGrantTxt
Boston Medical Center
One Boston Medical Ctr PL	Boston	MA	02118	043314093	501(c)(3)	$6,250	$0	BASIC RESEARCH
Regents of the University of California San Franc
3333 California St	San Francisco	CA	94143	946036493	501(c)(3)	$6,482	$0	BASIC RESEARCH
University of Washington
4333 Brooklyn Ave	Seattle	WA	981959472	916001537	501(c)(3)	$7,500	$0	BASIC RESEARCH
Regents of the University of California San Franc
3333 California St	San Francisco	CA	94143	946036493	501(c)(3)	$17,142	$0	BASIC RESEARCH
The Rockefeller University
1230 York Avenue	New York	NY	10065	131624158	501(c)(3)	$17,856	$0	BASIC RESEARCH
The J David Gladstone Institutes
1650 Owens Street	San Francisco	CA	94158	237203666	501(c)(3)	$31,250	$0	BASIC RESEARCH
University of California San Diego
9500 Gilman Drive	San Diego	CA	920930679	956006144	501(c)(3)	$33,334	$0	BASIC RESEARCH
Case Western Reserve University
10900 Euclid Ave 4930	Cleveland	OH	44106	341018992	501(c)(3)	$33,334	$0	BASIC RESEARCH
Case Western Reserve University
10900 Euclid Ave 4930	Cleveland	OH	44106	341018992	501(c)(3)	$33,334	$0	BASIC RESEARCH
Emory University
1599 Clifton Rd	Atlanta	GA	303224250	580566256	501(c)(3)	$33,334	$0	BASIC RESEARCH
Emory University
1599 Clifton Road	Atlanta	GA	303224250	580566256	501(c)(3)	$33,334	$0	BASIC RESEARCH
Johns Hopkins University
733 N Brdwy MRB 117	Baltimore	MD	21205	520595110	501(c)(3)	$33,334	$0	BASIC RESEARCH
State University of New York at Buffalo
520 Le Entrance Ste 211	Amherst	NY	14228	141368361	501(c)(3)	$33,334	$0	BASIC RESEARCH
Foundation for the National Institutes of Health
9650 Rockville Pike	Bethesda	MD	208143999	521986675	501(c)(3)	$53,332	$0	BASIC RESEARCH
Johns Hopkins University
733 N Brdwy MRB 117	Baltimore	MD	21205	520595110	501(c)(3)	$66,482	$0	BASIC RESEARCH
Yale University
266 Whitney Ave	New Haven	CT	06511	060646973	501(c)(3)	$66,666	$0	BASIC RESEARCH
University of Massachusetts Medical School
373 Plantation St	Worcester	MA	016052377	043167352	501(c)(3)	$66,666	$0	BASIC RESEARCH
University of Washington
4333 Brooklyn Ave	Seattle	WA	981959472	916001537	501(c)(3)	$66,667	$0	BASIC RESEARCH
Swarthmore College
500 College Avenue	Swarthmore	PA	19081	231352683	501(c)(3)	$66,667	$0	BASIC RESEARCH
The J David Gladstone Institutes
1650 Owens Street	San Francisco	CA	94158	237203666	501(c)(3)	$75,000	$0	BASIC RESEARCH
Emory University
1599 Clifton Rd	Atlanta	GA	303224250	580566256	501(c)(3)	$75,000	$0	BASIC RESEARCH
The Scripps Research Institute
130 Scripps Way	La Jolla	CA	33458	330435954	501(c)(3)	$75,000	$0	BASIC RESEARCH
The George Washington University
2121 I St NW Ste 601	Washington	DC	20052	530196584	501(c)(3)	$91,664	$0	BASIC RESEARCH
International AIDS Vaccine Initiative
125 Broad St 9th Fl	New York	NY	10004	133870223	501(c)(3)	$99,682	$0	BASIC RESEARCH
Oregon Health and Science University
3181 SW Sam Jackson Park	Portland	OR	97239	931176109	501(c)(3)	$99,972	$0	BASIC RESEARCH
University of Maryland at Baltimore
725 Lombard St S615	Baltimore	MD	21201	526002033	501(c)(3)	$99,998	$0	BASIC RESEARCH
Mayo Clinic College of Medicine
200 First Street SW	Rochester	MN	55905	416011702	501(c)(3)	$99,999	$0	BASIC RESEARCH
University of California San Francisco
3333 California St	San Francisco	CA	94143	946036493	501(c)(3)	$100,000	$0	BASIC RESEARCH
Boston University School of Medicine
650 Albany St EBRC 640	Boston	MA	02118	043314093	501(c)(3)	$100,000	$0	BASIC RESEARCH
Fred Hutchinson Cancer Research Center
1100 Fairview Ave N	Seattle	WA	98109	237156071	501(c)(3)	$100,000	$0	BASIC RESEARCH
Fred Hutchinson Cancer Research Center
1100 Fairview Ave N	Seattle	WA	98109	237156071	501(c)(3)	$100,000	$0	BASIC RESEARCH
University of Washington
4333 Brooklyn Ave	Seattle	WA	981959472	916001537	501(c)(3)	$299,966	$0	BASIC RESEARCH
University of California Los Angeles
11000 Kinross Ave	Los Angeles	CA	90095	956006143	501(c)(3)	$300,000	$0	BASIC RESEARCH
Trustees of the University of Pennsylvania
3451 Walnut St	Philadelphia	PA	191046250	231352685	501(c)(3)	$300,000	$0	BASIC RESEARCH
Beth Israel Deaconess Medical Center
330 Brookline Avenue	Boston	MA	02215	042103881	501(c)(3)	$497,990	$0	BASIC RESEARCH
Regents of the University of California San Franc
3333 California St	San Francisco	CA	94143	946036493	501(c)(3)	$499,956	$0	BASIC RESEARCH
Johns Hopkins University
733 N Brdwy MRB 117	Baltimore	MD	21205	520595110	501(c)(3)	$136,345	$0	GMT INITIATIVE
University of Washington
4333 Brooklyn Ave	Seattle	WA	981959472	916001537	501(c)(3)	$59,169	$0	RESEARCH
Johns Hopkins University
733 N Brdway MRB 117	Baltimore	MD	21205	520595110	501(c)(3)	$165,364	$0	RESEARCH
Harvard University
29 Oxford Street	Cambridge	MA	02138	042103580	501(c)(3)	$207,724	$0	RESEARCH
University of California San Francisco
3333 California St	San Francisco	CA	94143	946036493	501(c)(3)	$3,777,555	$0	RESEARCH
Johns Hopkins University
733 N BdRwy MRB 117	Baltimore	MD	21205	520595110	501(c)(3)	$155,864	$0	TREAT ASIA

Field	Value	IRS element (for citing)
Total501c3 Org	42	Total501c3OrgCnt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	GRANTS AND ASSISTANCE	FormAndLineReferenceDesc
Explanation	PART I, LINE 2 AMFAR PROVIDES GRANTS AND FELLOWSHIPS TO INDEPENDENT NOT-FOR-PROFIT ORGANIZATIONS THROUGH A PEER-REVIEW PROCESS. GRANT APPLICATIONS ARE FIRST REVIEWED BY THE FOUNDATION'S VOLUNTEER SCIENTIFIC ADVISORY COMMITTEE, WHICH COMPRISES RECOGNIZED EXPERTS IN THE MEDICAL, SCIENTIFIC, AND SOCIAL SCIENCES DISCIPLINES RELEVANT TO HIV AND AIDS. THE SCIENTIFIC ADVISORY COMMITTEE THEN SENDS ITS EVALUATIONS TO ONE OF THE THREE COMMITTEES (RESEARCH, GLOBAL INITIATIVES OR PUBLIC POLICY) OF THE FOUNDATION'S PROGRAM BOARD, WHICH SERVES IN AN ADVISORY CAPACITY TO THE BOARD OF TRUSTEES. AFTER A PROGRAM COMMITTEE HAS COMPLETED ITS REVIEW OF THE APPLICATIONS, IT PRESENTS ITS FUNDING RECOMMENDATIONS TO AMFAR'S EXECUTIVE COMMITTEE AND/OR THE FULL BOARD OF TRUSTEES FOR FINAL APPROVAL AND FUNDING AUTHORIZATION. GRANTS AND FELLOWSHIPS ARE PAYABLE OVER A ONE-TO-THREE-YEAR PERIOD, AND ARE REVOCABLE AT AMFAR'S OPTION IF THE RECIPIENT'S PERFORMANCE OR USE OF FUNDS IS NOT CONSISTENT WITH THE TERMS OF THE GRANT OR FELLOWSHIPS. IN CERTAIN CASES, THE ACTUAL AMOUNTS PAID UNDER GRANTS AND FELLOWSHIP AWARDS MAY BE LESS THAN THE ORIGINAL AWARD IF THE RECIPIENT DOES NOT USE THE FULL AMOUNT AWARDED. THEREFORE, A RESERVE FOR UNEXPENDED GRANTS AND FELLOWSHIPS HAS BEEN RECORDED. SUBAWARDS ARE GRANTS AWARDED TO NOT-FOR-PROFIT ORGANIZATIONS TO SUPPORT THE COSTS OF COLLABORATION AND PARTICIPATION IN HIV/AIDS-RELATED RESEARCH PROJECTS FOR WHICH AMFAR HAS SECURED RESTRICTED FUNDS. SUBAWARDS ARE PAYABLE OVER A ONE-YEAR PERIOD, ALTHOUGH ADVANCE PAYMENTS, IN FULL OR IN PART, MAY BE ISSUED FOLLOWING EXECUTION OF THE SUBAWARD AGREEMENT. SUBAWARDS ARE CONTINGENT UPON THE AVAILABILITY OF FUNDS AND ARE REVOCABLE IF THE RECIPIENTS' PERFORMANCE OR USE OF FUNDS IS NOT CONSISTENT WITH THE SUBAWARD TERMS.	ExplanationTxt

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Compensation Committee	Yes (X)	CompensationCommitteeInd
Independent Consultant	Yes (X)	IndependentConsultantInd
Compensation Survey	Yes (X)	CompensationSurveyInd
Board Or Committee Approval	Yes (X)	BoardOrCommitteeApprovalInd
Severance Payment	false	SeverancePaymentInd
Supplemental Nonqual Rtr Plan	Yes (true)	SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm	false	EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org	false	CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs	false	CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org	false	CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs	false	CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments	false	AnyNonFixedPaymentsInd
Initial Contract Exception	false	InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (14 entries)

TitleTitleTxt	Base Compensation Filing OrgBaseCompensationFilingOrgAmt	Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt	Bonus Filing OrganizationBonusFilingOrganizationAmount	Bonus Related OrganizationsBonusRelatedOrganizationsAmt	Other Compensation Filing OrgOtherCompensationFilingOrgAmt	Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt	Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt	Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt	Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt	Total Compensation Filing OrgTotalCompensationFilingOrgAmt	Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt	Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
Kevin Frost
Chief Executive Officer	$421,066	$0	$0	$0	$37,529	$0	$36,900	$0	$67,128	$0	$562,623	$0	$0	$0
Bradley Jensen
Assistant Treasurer, CFO	$276,038	$0	$0	$0	$0	$0	$18,378	$0	$51,715	$0	$346,131	$0	$0	$0
Rowena Johnston
ASST SEC, VP, RESEARCH	$203,095	$0	$0	$0	$0	$0	$14,279	$0	$16,840	$0	$234,214	$0	$0	$0
Edward Donnelly
Asst Treasurer, Controller	$163,157	$0	$0	$0	$0	$0	$11,861	$0	$15,430	$0	$190,448	$0	$0	$0
Eric Muscatell
Vice President of Development	$218,403	$0	$0	$0	$0	$0	$15,987	$0	$16,840	$0	$251,230	$0	$0	$0
Annette Sohn
Vice President, TREAT Asia PGM	$235,334	$0	$0	$0	$0	$0	$16,969	$0	$7,172	$0	$259,475	$0	$0	$0
AnnMarie Shannahan
Vice President, Public Info.	$234,029	$0	$0	$0	$0	$0	$16,474	$0	$16,840	$0	$267,343	$0	$0	$0
Gregorio Millet
Vice President, Public Policy	$188,800	$0	$0	$0	$0	$0	$13,767	$0	$31,524	$0	$234,091	$0	$0	$0
Andrew McInness
Director, Publications	$166,993	$0	$0	$0	$0	$0	$12,016	$0	$51,715	$0	$230,724	$0	$0	$0
Anthony Ancona
Vice President, Human Resource	$189,243	$0	$0	$0	$0	$0	$30,144	$0	$17,420	$0	$236,807	$0	$0	$0
Susan Doster
Chief Technology Officer	$149,646	$0	$0	$0	$0	$0	$10,967	$0	$39,948	$0	$200,561	$0	$0	$0
Bennah Serfaty
Sr Director of Communications	$132,347	$0	$0	$0	$0	$0	$9,551	$0	$51,715	$0	$193,613	$0	$0	$0
JONATHAN KEY
DIRECTOR, PHILANTHROPY	$190,220	$0	$0	$0	$0	$0	$13,764	$0	$39,948	$0	$243,932	$0	$0	$0
John F Logan JD PhD
AssT. Sec., Vp & GEN COUNSEL	$109,139	$0	$0	$0	$0	$0	$7,637	$0	$6,871	$0	$123,647	$0	$0	$0

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	COMPENSATION	FormAndLineReferenceDesc
Explanation	PART I, LINE 4 CHIEF EXECUTIVE OFFICER, KEVIN FROST, PARTICIPATED IN A SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN. IN CALENDAR YEAR 2017, AMFAR CONTRIBUTED $35,000 INTO MR. FROST'S NON-QUALIFIED RETIREMENT PLAN. THIS AMOUNT IS NOT REPORTED IN SCHEDULE J, PART II, COLUMN (C) BECAUSE THE CONTRIBUTED AMOUNT WAS DISTRIBUTED TO MR. FROST WITHIN THE SAME CALENDAR YEAR. INCLUDED IN SCHEDULE J COLUMN (B)(III) IS MR. FROST'S 2017 EMPLOYER-FUNDED 457(F) CONTRIBUTION OF $35,000.	ExplanationTxt

Schedule M IRS990ScheduleM

Field	Value	IRS element (for citing)
Works Of Art		WorksOfArtGrp
Art Historical Treasures		ArtHistoricalTreasuresGrp
Art Fractional Interest		ArtFractionalInterestGrp
Books And Publications		BooksAndPublicationsGrp
Clothing And Household Goods		ClothingAndHouseholdGoodsGrp
Cars And Other Vehicles		CarsAndOtherVehiclesGrp
Boats And Planes		BoatsAndPlanesGrp
Intellectual Property		IntellectualPropertyGrp

Securities Publicly Traded SecuritiesPubliclyTradedGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Contribution	9	ContributionCnt
Noncash Contributions Rpt F990	$28,210	NoncashContributionsRptF990Amt
Method Of Determining Revenues	sales price	MethodOfDeterminingRevenuesTxt

Field	Value	IRS element (for citing)
Securities Closely Held Stock		SecuritiesCloselyHeldStockGrp
Secur Prtnrshp Trust Intrsts		SecurPrtnrshpTrustIntrstsGrp
Securities Miscellaneous		SecuritiesMiscellaneousGrp
Qualified Contrib Hist Struct		QualifiedContribHistStructGrp
Qualified Contrib Other		QualifiedContribOtherGrp
Real Estate Residential		RealEstateResidentialGrp
Real Estate Commercial		RealEstateCommercialGrp
Real Estate Other		RealEstateOtherGrp
Collectibles		CollectiblesGrp
Food Inventory		FoodInventoryGrp
Drugs And Medical Supplies		DrugsAndMedicalSuppliesGrp
Taxidermy		TaxidermyGrp
Historical Artifacts		HistoricalArtifactsGrp
Scientific Specimens		ScientificSpecimensGrp
Archaeological Artifacts		ArchaeologicalArtifactsGrp

Other Non Cash Contri Table OtherNonCashContriTableGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Desc	Travel Vouchers	Desc
Contribution	47	ContributionCnt
Noncash Contributions Rpt F990	$19,515	NoncashContributionsRptF990Amt
Method Of Determining Revenues	sale price	MethodOfDeterminingRevenuesTxt

Field	Value	IRS element (for citing)
Any Property That Must Be Held	false	AnyPropertyThatMustBeHeldInd
Review Process Unusual NC Gifts	Yes (true)	ReviewProcessUnusualNCGiftsInd
Third Parties Used	false	ThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	FORM 990, SCHEDULE M, LINE 31	FormAndLineReferenceDesc
Explanation	TO THE EXTENT THAT AMFAR RECEIVES NON-STANDARD CONTRIBUTIONS, THE ORGANIZATION'S POLICY IS TO LIQUIDATE THOSE ITEMS INTO CASH FOR EVENTUAL USE IN SUPPORT OF THE ORGANIZATION'S MISSION.	ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (8 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
PROGRAM SERVICE ACCOMPLISHMENTS (1)	LINE 4A: RESEARCH: AMFAR SUPPORTS RESEARCH PROJECTS THAT EXPLORE NOVEL APPROACHES TO SCIENTIFICALLY SOUND BUT UNTESTED HYPOTHESES IN ALL AREAS OF RESEARCH ON HIV/AIDS, FUNDING GOAL-ORIENTED STUDIES THAT OFTEN LACK THE PRELIMINARY DATA REQUIRED FOR SUPPORT FROM TRADITIONAL GRANT MAKERS. THE FOUNDATION PLAYS A VITAL ROLE IN HIV/AIDS RESEARCH, IDENTIFYING CRITICAL GAPS IN KNOWLEDGE AND PROVIDING ESSENTIAL SEED MONEY THAT ENABLES GRANTEES AND FELLOWS TO TEST THE MERITS OF NEW CONCEPTS OR TECHNOLOGIES THAT SUBSEQUENTLY CAN BE VALIDATED THROUGH LARGE-SCALE STUDIES, SUCH AS THOSE FUNDED BY THE U.S. NATIONAL INSTITUTES OF HEALTH. AMFAR FELLOWSHIPS ALLOW TALENTED YOUNG RESEARCHERS TO CONDUCT ORIGINAL INVESTIGATIONS UNDER THE GUIDANCE OF EXPERIENCED SCIENTISTS, HELPING TO ENSURE THE LONG-TERM VITALITY OF AIDS RESEARCH. NEW GRANTS AND FELLOWSHIPS GRANTS AND FELLOWSHIPS ARE AWARDED THROUGH A RIGOROUS PROCESS OF PEER REVIEW BY A TEAM OF INDEPENDENT HIV/AIDS EXPERTS DRAWN LARGELY FROM THE VOLUNTEER SCIENTISTS ON AMFARS SCIENTIFIC ADVISORY COMMITTEE. GUIDED BY ITS SCIENTIFIC ADVISORS AND WITH THE APPROVAL OF ITS BOARD OF TRUSTEES, AMFAR PURSUES A STRATEGIC RESEARCH PLAN THAT FOCUSES ON THE PURSUIT OF A CURE FOR HIV. COUNTDOWN TO A CURE FOR AIDS IN 2015, AMFAR ANNOUNCED A $100 MILLION INVESTMENT STRATEGY TO SUPPORT ITS COUNTDOWN TO A CURE FOR AIDS INITIATIVE, WHICH IS AIMED AT DEVELOPING THE SCIENTIFIC BASIS FOR A CURE BY THE END OF 2020. THE STRATEGY REPRESENTS AN UNPRECEDENTED EXPANSION OF AMFARS GRANT MAKING AND IS DESIGNED TO PROVIDE SUPPORT TO ANY SCIENTIST OR TEAM OF INVESTIGATORS FOR ANY RESEARCH IDEA WITH THE POTENTIAL TO ADVANCE THE SEARCH FOR A CURE, AT ANY STAGE OF ITS DEVELOPMENT. IT IS STRUCTURED TO PROVIDE SUSTAINED SUPPORT FOR A WIDE RANGE OF STUDIES THAT ADVANCE BOTH EMERGING AND ESTABLISHED IDEAS. THE STRATEGY COMPRISES THE FOLLOWING COMPONENTS: - AMFAR INSTITUTE FOR HIV CURE RESEARCH ESTABLISHED IN 2015 WITH A $20 MILLION GRANT OVER FIVE YEARS TO THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE INSTITUTE IS THE CORNERSTONE OF AMFARS CURE RESEARCH. - INNOVATION GRANTS THESE TWO-YEAR AWARDS OF UP TO $200,000 EACH ENABLE RESEARCHERS TO TEST INNOVATIVE IDEAS SUPPORTED BY LIMITED PRELIMINARY DATA. - IMPACT GRANTS THESE GRANTS OF UP TO $2 MILLION EACH OVER FOUR YEARS SUPPORT THE IN-DEPTH DEVELOPMENT OF CONCEPTS ALREADY UNDERPINNED BY PRELIMINARY DATA SHOWING GENUINE POTENTIAL FOR ACHIEVING A CURE. - INVESTMENT GRANTS AIMED AT RECRUITING THE EXPERIENCE AND EXPERTISE OF SCIENTISTS FROM OUTSIDE THE FIELD OF HIV, THESE $1 MILLION GRANTS ARE AWARDED OVER A FOUR-YEAR PERIOD. GRANTEES MAY HAVE EXPERTISE IN FIELDS SUCH AS CANCER, NEUROSCIENCE, OR INFLAMMATORY DISEASE THAT CAN DIRECTLY INFORM EFFORTS TO CURE HIV. - ARCHE LAUNCHED IN 2010, THE AMFAR RESEARCH CONSORTIUM ON HIV ERADICATION, OR ARCHE, SUPPORTS COLLABORATIVE TEAMS OF SCIENTISTS IN THE U.S. AND AROUND THE WORLD WORKING ON A RANGE OF HIV CURE STRATEGIES. - OPPORTUNITY FUND THIS FUNDING MECHANISM ENABLES AMFAR TO RESPOND QUICKLY TO EMERGING AND UNFORESEEN RESEARCH OPPORTUNITIES. SINCE LAUNCHING THE COUNTDOWN IN 2014, WE HAVE AWARDED 73 COUNTDOWN GRANTS TOTALING MORE THAN $47 MILLION TO SUPPORT RESEARCH CONDUCTED BY 274 SCIENTISTS WORKING AT 92 INSTITUTIONS IN 16 COUNTRIES. INVESTMENT GRANTS IN FEBRUARY 2018, AMFAR ANNOUNCED A PAIR OF RESEARCH GRANTS THAT RENEW ITS SUPPORT FOR INNOVATIVE APPROACHES TO HIV CURE RESEARCH. TOTALING NEARLY $1 MILLION, THE INVESTMENT GRANTS ARE ALLOWING TWO COLLABORATIVE TEAMS OF HIV RESEARCHERS AND BIOENGINEERS TO CONTINUE PROJECTS INITIATED WITH AMFAR FUNDING AWARDED IN FEBRUARY 2017 INTO A SECOND PHASE. IN THE FIRST PHASE OF THEIR STUDY, ONE PAIR OF RESEARCHERS-DRS. HUI ZHANG AND WEIMING YANG OF JOHNS HOPKINS UNIVERSITY IN BALTIMORE-USED MASS SPECTROMETRY TO IDENTIFY MOLECULES ON THE SURFACE OF CELLS THAT DIFFERENTIATE LATENT RESERVOIRS FROM UNINFECTED CELLS. IN PHASE II, THEY ARE DETERMINING WHETHER THESE NEWLY IDENTIFIED PROTEINS ARE ABLE TO DISTINGUISH THE RESERVOIR IN PATIENT SAMPLES. IN PHASE I OF THEIR PROJECT, THE OTHER PAIR-DRS. KIM WOODROW AND KEITH JEROME OF THE UNIVERSITY OF WASHINGTON IN SEATTLE-FORMULATED NEW DRUG COMBINATIONS LOADED ONTO NANOPARTICLES (HIGHLY MALLEABLE CARRIERS THAT ARE A THOUSAND TIMES SMALLER THAN A CELL) TARGETING THE LATENT HIV RESERVOIR. THE NANOPARTICLES PREFERENTIALLY DELIVERED LATENCY REVERSING AGENTS TO CD4 T CELLS, WHICH REAWAKENED THE RESERVOIR, A PREREQUISITE FOR IMMUNE DIRECTED KILLING OF THE CELL IN A "SHOCK AND KILL" APPROACH TO CURING HIV. IN PHASE II, THE RESEARCHERS ARE TESTING THE LOADED NANOPARTICLES AND MEASURING THEIR EFFECTS ON THE RESERVOIR IN A PRECLINICAL STUDY. IMPACT GRANTS IN SEPTEMBER 2018, AMFAR AWARDED GRANTS TOTALING $828,000 TO ADVANCE TWO CRITICAL AREAS OF HIV CURE RESEARCH. FIVE GRANTS WILL ARE SUPPORTING A RANGE OF EFFORTS TO UNDERSTAND THE MECHANISMS AND PREDICTORS OF POST-TREATMENT CONTROL, WHEREBY A SMALL NUMBER OF INDIVIDUALS ARE ABLE TO CONTROL THEIR HIV AFTER STOPPING TREATMENT. THREE ADDITIONAL GRANTEES ARE STUDYING HIV-POSITIVE POPULATIONS IN LOW-AND MIDDLE-INCOME COUNTRIES TO LOOK FOR DIFFERENCES IN HOW THE PERSISTENT VIRAL RESERVOIR-THE PRINCIPAL BARRIER TO A CURE-FORMS AND CHANGES OVER TIME. IN A COHORT OF POST-TREATMENT CONTROLLERS FROM ONE OF THE LARGEST HIV CLINICAL TRIAL NETWORKS IN THE WORLD, DR. JONATHAN LI OF BRIGHAM AND WOMEN'S HOSPITAL IN BOSTON IS USING NEXT-GENERATION GENOMIC SEQUENCING TO INVESTIGATE WHETHER CHARACTERISTICS OF THE VIRUS OR IMMUNOLOGIC RESPONSES CAN PREDICT POST-TREATMENT CONTROL. ANOTHER GRANTEE, DR. GODWIN NCHINDA, A RESEARCHER IN YAOUNDE, CAMEROON, HAS IDENTIFIED A COHORT OF WOMEN WHO RECEIVED ANTIRETROVIRAL THERAPY (ART) DURING PREGNANCY AND CONTINUE TO CONTROL THEIR VIRUS DESPITE DISCONTINUING TREATMENT AFTER GIVING BIRTH. HE IS STUDYING THIS GROUP TO DETERMINE THE CAUSES OF THEIR VIRAL CONTROL. THE MAJORITY OF WHAT IS KNOWN ABOUT HIV COMES FROM RESEARCH DONE IN HIGH-INCOME COUNTRIES, WHERE HIV SUBTYPE B PREDOMINATES. HOWEVER, SUBTYPE B ACCOUNTS FOR JUST 12% OF GLOBAL HIV INFECTIONS. DR. EDWARD KANKAKA OF THE RAKAI HEALTH SCIENCES PROGRAM IN KAMPALA, UGANDA, HAS SHOWN THAT NON-B HIV-POSITIVE UGANDANS HAD A SMALLER RESERVOIR OF PERSISTENT VIRUS COMPARED TO PEOPLE INFECTED WITH SUBTYPE B. DR. KANKAKA IS EXPANDING THESE STUDIES TO DETERMINE WHETHER FORMATION AND MAINTENANCE OF THE RESERVOIR DIFFER IN THESE POPULATIONS. IN DURBAN, SOUTH AFRICA, DR. ALEX SIGAL IS EXAMINING THE INFLUENCE OF TUBERCULOSIS-A COMMON CO-INFECTION IN LOW- AND MIDDLE-INCOME COUNTRIES-ON THE HIV RESERVOIR. HE IS EXPLORING WHETHER THE IMMUNE RESPONSE TO TB ITSELF ALTERS HIV REACTIVATION-A KEY COMPONENT OF THE "SHOCK AND KILL" APPROACH TO CURING HIV. THE REMAINING GRANTEES ARE DR. MOHAMED ABDEL-MOHSEN OF THE WISTAR INSTITUTE, PHILADELPHIA, PA; DR. JOHN FRATER OF OXFORD UNIVERSITY, UK; DR. REENA RAJASURIAR OF THE UNIVERSITY OF MALAYA, KUALA LUMPUR, MALAYSIA; AND DR. RUI WANG OF HARVARD PILGRIM HEALTHCARE INSTITUTE, WELLESLEY, MA. ARCHE (AMFAR RESEARCH CONSORTIUM ON HIV ERADICATION) IN SEPTEMBER 2018, AMFAR AWARDED $800,000 IN NEW FUNDING TO SIX TEAMS OF RESEARCHERS DEVELOPING AN AMBITIOUS GENE THERAPY-BASED APPROACH TO CURING HIV. THE AWARD LAUNCHES A CRITICAL NEW PHASE IN A STUDY INITIATED IN 2017. IN A THREE-PRONGED ATTACK ON THE HIV RESERVOIR, THE RESEARCHERS WILL EMPLOY BROADLY NEUTRALIZING ANTIBODIES, CAR STEM CELLS-CELLS GENETICALLY REPROGRAMMED TO RECOGNIZE AND ATTACK DISEASE CELLS-AND MOLECULAR SCISSORS TARGETING THE VIRUS. THE GRANT WAS SUPPORTED IN PART BY THE BILL AND MELINDA GATES FOUNDATION. THE INVESTIGATORS ARE: DR. HILDEGARD BUNING OF HANNOVER MEDICAL SCHOOL, GERMANY; DR. KEITH JEROME OF THE UNIVERSITY OF WASHINGTON, SEATTLE; DR. HANS-PETER KIEM OF FRED HUTCHINSON CANCER RESEARCH CENTER, SEATTLE; DR. SCOTT KITCHEN OF UCLA; DR. YASUHIRO TAKEUCHI OF UNIVERSITY COLLEGE LONDON; DR. DREW WEISSMAN OF UNIVERSITY OF PENNSYLVANIA IN PHILADELPHIA; AND DR. RICHARD WYATT OF THE SCRIPPS RESEARCH INSTITUTE IN LA JOLLA, CA. MATHILDE KRIM FELLOWSHIPS IN OCTOBER 2017, AMFAR ANNOUNCED THE RECIPIENTS OF THE 2017 MATHILDE KRIM FELLOWSHIPS IN BASIC BIOMEDICAL RESEARCH: DANIELA MONACO, PH.D., AT EMORY UNIVERSITY IN ATLANTA, GA; GABRIEL OZOROWSKI, PH.D., AT THE SCRIPPS RESEARCH INSTITUTE IN SAN DIEGO, CA; AND JONATHAN RICHARD, PH.D., AT THE UNIVERSIT DE MONTREAL, CENTRE DE RECHERCHE DU CHUM IN MONTREAL, CANADA. THE 2018 KRIM FELLOW, DR. YEN-TING LAI OF THE VACCINE RESEARCH CENTER/NATIONAL INSTITUTES OF HEALTH IN BETHESDA, MD, WAS ANNOUNCED IN SEPTEMBER 2018. THE KRIM FELLOWSHIPS SUPPORT BRIGHT YOUNG SCIENTISTS ADVANCING INNOVATIVE SOLUTIONS TO HIV/AIDS. EACH FELLOW IS AWARDED APPROXIMATELY $150,000 OVER TWO YEARS.
PROGRAM SERVICE ACCOMPLISHMENTS (1) CONT.	PUBLISHED RESEARCH RESEARCH STUDIES MAKE THE GREATEST IMPACT ON THE HIV FIELD AND ON THE BROADER SCIENTIFIC COMMUNITY WHEN THEY ARE PUBLISHED IN SCIENTIFIC JOURNALS. IN FY2018, A RECORD 80 SCIENTIFIC PUBLICATIONS RESULTED FROM AMFAR-FUNDED RESEARCH. EXAMPLES INCLUDE: LEARNING HOW ANTIBODIES CAN CURE HIV KILLING HIV RESERVOIR CELLS WOULD POTENTIALLY ERADICATE HIV FROM THE BODY. IN THREE JOURNAL ARTICLES PUBLISHED IN DECEMBER 2017, AMFAR-FUNDED SCIENTISTS DISCUSSED RECENT ADVANCES IN UNDERSTANDING HOW IMMUNE SYSTEM CELLS USE ANTIBODIES TO KILL HIV-INFECTED CELLS VIA ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY (ADCC). ADCC IS AN IMMUNE RESPONSE IN WHICH ANTIBODIES ACT AS HOMING DEVICES TO RECRUIT IMMUNE CELLS THAT TARGET AND KILL INFECTED CELLS. IN A STUDY PUBLISHED IN THE JOURNAL RETROVIROLOGY, DRS. AMY CHUNG OF THE UNIVERSITY OF MELBOURNE, AUSTRALIA, AND GALIT ALTER OF THE RAGON INSTITUTE OF MGH, MIT, AND HARVARD UNIVERSITY, WROTE ABOUT A PLATFORM OF TECHNIQUES CALLED SYSTEMS SEROLOGY, WHICH THEY DEVELOPED TO EXPLORE THE FUNCTIONALITY OF ANTIBODIES. DR. CHUNG IS ALSO STUDYING THE MECHANISMS OF INTERACTION BETWEEN VACCINES THAT PRODUCE IGA, A TYPE OF ANTIBODY PRESENT ONLY IN MUCOSAL TISSUES, AND IGG, AN ANTIBODY PRESENT IN THE BLOOD, TO PROVIDE PARTIAL PROTECTION AGAINST HIV. WRITING IN THE JOURNAL EBIOMEDICINE, SHE COMMENTS ON A STUDY CARRIED OUT BY RESEARCHERS AT THE UNIVERSITY OF BUENOS AIRES IN ARGENTINA THAT SUPPORTS HER OBSERVATIONS THAT THE RATIO OF IGG TO IGA CORRELATES WITH THE KILLING ACTION OF ANTIBODIES. AND IN A THIRD STUDY PUBLISHED IN THE JOURNAL VIROLOGY, DR. ANDRES FINZI OF THE CENTRE DE RECHERCHE DU CHUM IN MONTREAL REPORTS ON THE SUSCEPTIBILITY OF THE VIRAL PROTEIN ENV-PRESENT ON THE SURFACE OF ACTIVELY INFECTED CELLS-TO ANTIBODIES. NEW RESEARCH POINTS TO THE POWERFUL EFFECT OF ESTROGEN ON THE HIV RESERVOIR A STUDY LED BY AMFAR-FUNDED SCIENTIST DR. JOHNATHAN KARN OF CASE WESTERN RESERVE UNIVERSITY, PUBLISHED IN THE AUGUST 2018 ISSUE OF THE PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, REVEALS THAT ESTROGEN HAS A SIGNIFICANT EFFECT ON THE PERSISTENT HIV RESERVOIR. FOLLOWING A COHORT OF 26 MEN AND 26 WOMEN, THE RESEARCHERS FOUND THAT WOMEN HAVE A SMALLER "INDUCIBLE" RESERVOIR THAN MEN. IN OTHER WORDS, WHILE THE TOTAL SIZE OF THE RESERVOIR APPEARS TO BE THE SAME FOR BOTH SEXES, WOMEN HAVE A SMALLER AMOUNT OF RESERVOIR VIRUS THAT CAN BE COAXED OUT OF HIDING BY SO-CALLED LATENCY-REVERSING AGENTS. THE FINDING HAS IMPORTANT IMPLICATIONS FOR CURE RESEARCH, SPECIFICALLY THE "SHOCK AND KILL" STRATEGY, WHICH AIMS TO SHOCK HIV OUT OF THE RESERVOIR SO THAT IT CAN BE KILLED BY THE IMMUNE SYSTEM OR SOME OTHER KILLING AGENT. THE STUDY RAISES THE QUESTION OF WHETHER THIS STRATEGY WOULD BE LESS EFFECTIVE IN WOMEN, GIVEN THEIR SMALLER INDUCIBLE RESERVOIR, AND CALLS FOR FURTHER INVESTIGATIONS INTO SEX DIFFERENCES IN LATENCY REVERSAL AND HIV PERSISTENCE. HIV CURE SUMMIT A WIDE RANGE OF PERSPECTIVES-FROM CLINICIANS, BIOMEDICAL RESEARCHERS AND SOCIAL SCIENTISTS TO PATIENTS AND COMMUNITY LEADERS-WERE PRESENTED ON NOVEMBER 28 AT AMFAR'S 2017 WORLD AIDS DAY HIV CURE SUMMIT AT THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (UCSF), HOME TO THE AMFAR INSTITUTE FOR HIV CURE RESEARCH. SCIENTIST AND PHYSICIAN PARTICIPANTS INCLUDED DIRECTOR OF THE AMFAR INSTITUTE DR. PAUL VOLBERDING; INSTITUTE BOARD MEMBERS DRS. STEVEN DEEKS, WARNER GREENE, SATISH PILLAI, PETER HUNT, AND NADIA ROAN; DR. JUDITH AUERBACH OF UCSF; AND AMFAR VICE PRESIDENT OF RESEARCH DR. ROWENA JOHNSTON. COMMUNITY PANELISTS INCLUDED TREATMENT ACTIVISTS AND AMFAR INSTITUTE COMMUNITY ADVISORY BOARD MEMBERS LYNDA DEE, JEFF TAYLOR, LOREN JONES AND ROB NEWELLS. CLARK HAWLEY AND LUIS CANALES SHARED THEIR PERSONAL EXPERIENCES OF PARTICIPATING IN HIV CURE RESEARCH. THE SUMMIT WAS ORGANIZED AROUND A SERIES OF THREE PANEL DISCUSSIONS. THE FIRST TWO, MODERATED BY DR. VOLBERDING, FOCUSED ON SOME OF THE POTENTIALLY CURATIVE AGENTS AND STRATEGIES THAT ARE CURRENTLY BEING DEVELOPED AND TESTED. THE FINAL PANEL, LED BY DR. AUERBACH, SERVED AS A DEBATE OVER THE RELATIVE MERITS OF CURE, I.E., TOTAL ERADICATION OF THE VIRUS, VERSUS POST-TREATMENT CONTROL. HIV RESEARCH SUMMIT IN BRAZIL AMFAR HOSTED ITS SECOND ANNUAL HIV RESEARCH SUMMIT AT THE UNIVERSITY OF SAO PAULO, BRAZIL, ON APRIL 10, 2018. THE CONFERENCE, WHICH DREW MORE THAN 150 COMMUNITY MEMBERS, MEDICAL STUDENTS, HEALTHCARE PROFESSIONALS, AND REPRESENTATIVES FROM SAO PAULO-BASED NONGOVERNMENTAL ORGANIZATIONS, WAS HELD IN CONJUNCTION WITH THE ADVANCED COURSE ON HIV PATHOGENESIS AT THE UNIVERSITYS SCHOOL OF MEDICINE. SPEAKERS INCLUDED DR. ROWENA JOHNSTON, AMFAR VICE PRESIDENT AND DIRECTOR OF RESEARCH; DR. STEVEN DEEKS, PROFESSOR OF MEDICINE, UNIVERSITY OF CALIFORNIA, SAN FRANCISCO; DR. BRAD JONES, ASSISTANT PROFESSOR, THE GEORGE WASHINGTON UNIVERSITY; AND DR. LISHOMWA NDHLOVU, ASSOCIATE PROFESSOR, JOHN A. BURNS SCHOOL OF MEDICINE, UNIVERSITY OF HAWAII. THINK TANKS CONSISTENT WITH AMFARS COMMITMENT TO INVESTIGATE EVERY AVENUE THAT MAY LEAD TO A CURE, THE FOUNDATION REGULARLY HOSTS THINK TANKS THAT BRING TOGETHER LEADING INVESTIGATORS IN VARIOUS FIELDS. IN OCTOBER 2017, AMFAR HOSTED A THINK TANK IN ITS NEW YORK CITY OFFICE WITH ITS ARCHE GENE THERAPY GRANTEES AND SOME EXPERTS ON NON-HUMAN PRIMATE RESEARCH. THE THINK TANK DISCUSSED THE ARCHE PROJECTS, IDENTIFIED OPPORTUNITIES FOR COLLABORATION, AND CLARIFIED AMFARS GOALS AND PHILOSOPHY FOR THE FUTURE OF THIS RESEARCH. IN JANUARY 2018, AMFAR DIRECTOR OF RESEARCH DR. ROWENA JOHNSTON AND PROGRAM CONSULTANT DR. JEFFREY LAURENCE TRAVELED TO BERLIN FOR AN ICISTEM THINK TANK. ICISTEM, CREATED AND FUNDED BY AMFAR THROUGH ITS COUNTDOWN TO A CURE FOR AIDS INITIATIVE, IS A CONSORTIUM OF EUROPEAN RESEARCHERS THAT HAS BEEN WORKING TO REPLICATE THE CASE OF "THE BERLIN PATIENT. (THE "LONDON PATIENT," REPORTED IN MARCH 2019 BY ICISTEM RESEARCHER DR. RAVI GUPTA, WAS THE FIRST OF THE GROUPS PATIENTS TO GO INTO HIV REMISSION.) AT THE END OF APRIL 2018, DRS. JOHNSTON AND LAURENCE HELD ANOTHER THINK TANK IN AMFARS NEW YORK CITY OFFICE TO PROVIDE UPDATES ON RESEARCH PROGRESS SO FAR AND TO DECIDE HOW BEST TO CONTINUE EFFORTS TOWARDS BUILDING A GENE THERAPY CURE FOR HIV. PROGRAM SERVICE ACCOMPLISHMENTS (2) LINE 4B: TREAT ASIA: AMFARS TREAT ASIA (THERAPEUTICS RESEARCH, EDUCATION, AND AIDS TRAINING IN ASIA) PROGRAM IS A NETWORK OF HOSPITALS, CLINICS, AND RESEARCH INSTITUTIONS WORKING WITH CIVIL SOCIETY TO ENSURE THE SAFE AND EFFECTIVE DELIVERY OF TREATMENTS FOR HIV AND ITS CO-INFECTIONS TO ADULTS AND CHILDREN ACROSS THE ASIA-PACIFIC THROUGH RESEARCH, EDUCATION, AND ADVOCACY OF EVIDENCE-BASED HIV-RELATED POLICIES. THE TREAT ASIA NETWORK ENCOMPASSES 21 ADULT AND 20 PEDIATRIC SITES THROUGHOUT THE REGION, WHICH COLLABORATE ON A VARIETY OF PROJECTS. TREAT ASIA SCIENTISTS PRODUCED 20 PUBLICATIONS IN PEER-REVIEWED MEDICAL JOURNALS IN FY2018. INTERNATIONAL AIDS DATABASE SINCE 2006, TREAT ASIA HAS MANAGED THE ASIA-PACIFIC SECTION OF THE INTERNATIONAL EPIDEMIOLOGIC DATABASES TO EVALUATE AIDS (IEDEA), A GLOBAL COLLABORATION ESTABLISHED BY THE U.S. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES. IN FY2018 IEDEA FUNDED MANY TREAT ASIA STUDIES, INCLUDING (ALONG WITH VIIV HEALTHCARE) THE THIRD YEAR OF STAY (STUDY OF TRANSITIONING ASIAN YOUTH), WHICH IS DOCUMENTING THE EXPERIENCE OF HIV-INFECTED YOUNG ADULTS WHO ARE TRANSITIONING FROM PEDIATRIC TO ADULT CARE. ANOTHER MAJOR IEDEA-FUNDED STUDY WAS THE SECOND YEAR OF THE INITIATIVE CALLED GRADUATE: A GLOBAL FRAMEWORK OF DATA COLLECTION USED FOR ADOLESCENT HIV TRANSITION EVALUATION. LED BY TREAT ASIA DIRECTOR DR. ANNETTE SOHN AND DR. MARY-ANN DAVIES OF THE UNIVERSITY OF CAPE TOWN, SOUTH AFRICA, GRADUATE, WHICH IS BEING CONDUCTED IN IN MALAWI, SOUTH AFRICA, AND THAILAND, AIMS TO IMPROVE HOW CLINICAL AND PROGRAM DATA ON ADOLESCENTS LIVING WITH HIV ARE ORGANIZED AND STUDIED IN RESOURCE-LIMITED SETTINGS. TREAT ASIA HIV OBSERVATIONAL DATABASE (TAHOD) IN 2002, TREAT ASIA PIONEERED THE REGIONS FIRST ADULT OBSERVATIONAL DATABASE FOR HIV/AIDS, WHICH NOW INCLUDES ANONYMOUS DATA FROM NEARLY 10,000 PATIENTS AT 21 CLINICAL SITES IN 12 COUNTRIES. THE INFORMATION GATHERED IN THE DATABASE INFORMS THE DEVELOPMENT OF MORE EFFECTIVE RESEARCH AND TREATMENT PROGRAMS AND HELPS DEFINE TREATMENT STANDARDS SPECIFIC TO HIV/AIDS IN ASIA. TREAT ASIA PEDIATRIC HIV OBSERVATIONAL DATABASE (TAPHOD) THE TREAT ASIA PEDIATRIC HIV OBSERVATIONAL DATABASE (TAPHOD) IS A REGIONAL PEDIATRIC HIV STUDY SET UP BY TREAT ASIA IN 2006. IT WAS MODELED AFTER THE ADULT DATABASE AND INCLUDES DATA FROM MORE THAN 6,400 CHILDREN AND ADOLESCENTS AT 18 CLINICAL SITES IN CAMBODIA, INDIA, INDONESIA, MALAYSIA, THAILAND, AND VIETNAM.
PROGRAM SERVICE ACCOMPLISHMENTS (2) CONT.	ASSESSING FAILING SECOND-LINE HIV TREATMENT REGIMENS: THE TASER-2 STUDY THE TREAT ASIA STUDY TO EVALUATE RESISTANCE 2 (TASER-2) WAS INITIATED IN 2016 TO IMPROVE ASSESSMENT OF VIRAL FAILURE AND ASSOCIATED HIV DRUG RESISTANCE IN HIV-INFECTED ADULTS ON SECOND-LINE ART. THE STUDY IS FUNDED BY VIIV HEALTHCARE AND THE US NATIONAL INSTITUTES OF HEALTH THROUGH THE IEDEA GLOBAL COHORT CONSORTIUM. OVER 2,400 PARTICIPANTS HAVE BEEN ENROLLED ACROSS 12 PARTICIPATING SITES IN CAMBODIA, HONG KONG SAR, INDIA, INDONESIA, JAPAN, MALAYSIA, THE PHILIPPINES, SINGAPORE, SOUTH KOREA, AND VIETNAM. THE STUDY WILL PROVIDE DETAILED ANALYSIS OF THE PREVALENCE OF VIROLOGIC FAILURE, ASSOCIATED FACTORS, AND HIV DRUG RESISTANCE MUTATIONS. THIS INFORMATION WILL HELP TO BETTER PREDICT THE NEED FOR THIRD-LINE ART REGIMENS IN THE REGION, AS WELL AS TO FACILITATE ADVOCACY EFFORTS FOR INCLUSION OF THIRD-LINE OPTIONS IN NATIONAL TREATMENT GUIDELINES AND EXPANSION OF ROUTINE VIRAL LOAD TESTING CAPACITIES IN THE REGION. TAHOD LOW-INTENSITY TRANSFER (TAHOD-LITE) LAUNCHED IN 2015, TAHOD LOW-INTENSITY TRANSFER (TAHOD-LITE) CONTAINS DATA FROM OVER 37,000 HIV-POSITIVE PATIENTS ACROSS 10 TREAT ASIA NETWORK SITES. AS AN EXTENSION OF TAHOD, TAHOD-LITE AIMS TO INCREASE THE SCOPE OF ADULT DATA COLLECTION BY GATHERING A SUBSET OF CORE VARIABLES FROM THE ENTIRE COHORT OF HIV-INFECTED PATIENTS WHO HAVE SOUGHT CARE AT SELECTED TAHOD SITES. EVALUATING DEPRESSION AND ANXIETY IN THAI ADOLESCENTS WITH HIV AS PART OF TREAT ASIAS INITIATIVE TO ADDRESS THE MENTAL HEALTH CONCERNS OF ADOLESCENTS LIVING WITH HIV IN ASIA, A STUDY FUNDED THROUGH THE US NATIONAL INSTITUTES OF HEALTH IEDEA COLLABORATION IS EVALUATING THE PREVALENCE AND CLINICAL COURSE OF DEPRESSION AND ANXIETY IN THAI ADOLESCENTS WITH HIV. LED BY DR. TAVITIYA SUDJARITRUK OF CHIANG MAI UNIVERSITY IN CHIANG MAI, THAILAND, THE STUDY, WHICH BEGAN IN EARLY 2018, IS COMPARING DEPRESSION AND ANXIETY IN 150 ADOLESCENTS LIVING WITH HIV AND 150 MATCHED CONTROLS WITHOUT HIV. ADDRESSING ADULT MENTAL HEALTH IN JANUARY 2018, TREAT ASIA ORGANIZED A THINK TANK IN BANGKOK ON MENTAL HEALTH ISSUES IN ADULTS LIVING WITH HIV IN ASIA. LIKE CHILDREN AND ADOLESCENTS, ADULTS LIVING WITH HIV HAVE A HIGHER PREVALENCE OF ANXIETY AND DEPRESSION COMPARED WITH THEIR UNINFECTED PEERS, AND THESE ISSUES HAVE BEEN INADEQUATELY STUDIED AND TREATED. THE THINK TANK BROUGHT TOGETHER RESEARCHERS, CLINICIANS, AND PSYCHOLOGISTS FROM ACROSS ASIA AND FROM COLUMBIA UNIVERSITY IN NEW YORK CITY. PARTICIPANTS HIGHLIGHTED SOME CENTRAL ISSUES, AS WELL AS STRENGTHS, IN THEIR COUNTRIES APPROACHES AND RESOURCES FOR ASSESSING AND TREATING DEPRESSION IN ADULTS WITH HIV. THEY PROCEEDED TO CONSIDER RESEARCH, POLICY, AND CAPACITY DEVELOPMENT ACTIVITIES THAT MIGHT HELP ADDRESS SOME OF THE GAPS IN MENTAL HEALTH MANAGEMENT IN HIV CARE SETTINGS IN THE REGION. EMPOWERING YOUTH ADVOCATES THE SECOND CLASS OF TREAT ASIA'S YOUTH ACATA-ASIA COMMUNITY FOR AIDS TREATMENT AND ADVOCACY-CONTINUED ITS TWO-YEAR LEADERSHIP TRAINING PROGRAM IN FY2018. LAUNCHED IN 2015 WITH SUPPORT FROM VIIV HEALTHCARES POSITIVE ACTION FOR ADOLESCENTS PROGRAM, THE YOUTH ACATA PROGRAM AIMS TO EDUCATE PARTICIPANTS ABOUT HIV AND ANTIRETROVIRAL THERAPY AND CONNECT THEM TO OTHER HIV-POSITIVE YOUTH IN THE REGION. YOUTH ACATA MEMBERS HAVE BEGUN PARTICIPATING IN GLOBAL YOUTH PROGRAMS, INCLUDING SPARK17 AND THE INTERNATIONAL AIDS SOCIETYS ADOLESCENT TREATMENT COALITION. THE CURRENT GROUP INCLUDES YOUNG PEOPLE FROM MALAYSIA, INDIA, INDONESIA, THE PHILIPPINES, AND TAIWAN. HELPING ADOLESCENTS TRANSITION TO ADULT CARE AS PART OF ITS ONGOING EFFORTS TO IMPROVE THE PROCESS OF ADOLESCENT TRANSITION TO ADULT HIV CARE, TREAT ASIA AND REGIONAL PARTNERS CONDUCTED TRAININGS IN CAMBODIA, INDONESIA, MALAYSIA, THAILAND, AND VIETNAM FOR CLINICIANS WHO WORK WITH HIV-POSITIVE CHILDREN AND ADOLESCENTS TO HELP THEM BETTER PREPARE FOR THE MOVE TO ADULT HIV CARE. THE DAY-LONG SESSIONS FOCUSED ON CLINICAL CHALLENGES IN LONG-TERM HIV CARE AND TREATMENT, COMMUNICATION AND MANAGEMENT STRATEGIES TO IMPROVE RETENTION IN HIV CARE, AND ADOLESCENT HIV TRANSITION CARE MODELS. ADVOCATING FOR HIV AND CO-INFECTION TREATMENT ACCESS IN OCTOBER 2017, AMFARS PUBLIC POLICY OFFICE AND TREAT ASIA ORGANIZED A CONSULTATION IN BANGKOK WITH EXPERTS FROM LOCAL, NATIONAL, REGIONAL, AND INTERNATIONAL ORGANIZATIONS IN 11 COUNTRIES IN ASIA, EUROPE, AFRICA, AND NORTH AMERICA. THEY MET TO DISCUSS "ESSENTIAL STANDARDS" FOR VOLUNTARY LICENSES-ARRANGEMENTS WHEREBY A PATENT HOLDER ALLOWS OTHERS TO MANUFACTURE, IMPORT, AND/OR DISTRIBUTE ITS PATENTED DRUG-IN ORDER TO ENSURE GENUINE ACCESS. IN OCTOBER 2017, TREAT ASIA AND THE INTERNATIONAL ASSOCIATION COALITION PLUS BEGAN A NEW PARTNERSHIP TO IMPROVE HEPATITIS C (HCV) DIAGNOSIS AND TREATMENT ACCESS IN ASIA THROUGH THE UNITAID-FUNDED "HIV/HCV DRUG AFFORDABILITY PROJECT." THE PARTNERSHIPS GOAL IS TO BUILD LOCAL MOVEMENTS TOWARDS IMPLEMENTING NATIONAL TREATMENT PROGRAMS. A KEY STRATEGY HAS BEEN TO ENGAGE AND PARTNER WITH LOCAL CIVIL SOCIETY ORGANIZATIONS AND POLICY MAKERS TO ADVANCE ACCESS TOGETHER. IN NOVEMBER AND DECEMBER 2017, TREAT ASIA ORGANIZED TWO TRAININGS ON HEPATITIS B AND C AND THE IMPORTANCE OF ADDRESSING THESE DISEASES IN THE CONTEXT OF HIV CO-INFECTION. THE FIRST TRAINING, FOR COMMUNITY MEMBERS AND TREATMENT ADVOCATES FROM EIGHT COUNTRIES, AIMED TO SIMPLIFY WORLD HEALTH ORGANIZATION (WHO) HEPATITIS B AND C SCREENING AND TREATMENT GUIDELINES. THE SECOND FOCUSED ON SUPPORTING IMPLEMENTATION OF THE WHO GUIDELINES AT THE NATIONAL LEVEL, AND FAMILIARIZING CLINICIANS WITH THE GUIDELINES. IN COLLABORATION WITH THE WORLD HEALTH ORGANIZATION (WHO) SOUTH EAST ASIA REGIONAL OFFICE (SEARO) AND WESTERN PACIFIC REGIONAL OFFICE (WPRO), TREAT ASIA ORGANIZED A ROUNDTABLE DISCUSSION IN BANGKOK IN SEPTEMBER 2018 TITLED "ENHANCING ACCESS TO NEWER HIV AND HEPATITIS C MEDICINES." MANAGERS FROM INTELLECTUAL PROPERTY OFFICES, NATIONAL REGULATORY BODIES, AND HIV PROGRAMS IN NINE ASIAN COUNTRIES ATTENDED, ALONG WITH REPRESENTATIVES FROM THE CLINTON HEALTH ACCESS INITIATIVE, MEDICINES PATENT POOL, DRUGS FOR NEGLECTED DISEASES INITIATIVE, UNAIDS, AND THE WHO. INTRODUCING PREP TO THE PHILIPPINES IN FY 2018, PROJECT PREPPY, A TWO-YEAR PILOT PROJECT BEING CONDUCTED AT TWO CLINICS IN MANILA, THE PHILIPPINES, COMPLETED ENROLLMENT AND COMMENCED EVALUATING COMMUNITY-BASED, PEER-DRIVEN DELIVERY OF ANTIRETROVIRAL PRE-EXPOSURE PROPHYLAXIS (PREP). PROJECT PREPPY IS AN EFFORT TO CURB THE RAPID SPREAD IN RECENT YEARS OF HIV AMONG MSM AND TRANSGENDER INDIVIDUALS IN THE PHILIPPINES. AMFAR IS AMONG SEVERAL ORGANIZATIONS INVOLVED IN THE STUDY, A MULTIAGENCY COLLABORATION WITH EXPERTS FROM GOVERNMENT, ACADEMIA, AND MULTILATERAL AND NONGOVERNMENTAL ORGANIZATIONS. BASED ON EXPERIENCES FROM THE FIRST YEAR OF THE PROJECT, THE PHILIPPINES IS MOVING FORWARD TO AN EXPANSION OF PREP SERVICES IN OTHER AREAS OF THE COUNTRY. PUBLICATIONS IN FY2018, TREAT ASIA CREATED THE SECOND AND THIRD IN A SERIES OF INFOGRAPHICS TITLED WHY HAS ASIA FALLEN BEHIND ON HIV/AIDS TO ILLUSTRATE THE STAGNATION IN HIV PROGRAM COVERAGE IN THE ASIA-PACIFIC. THE STAGNATION IS A REMINDER TO GOVERNMENTS, CIVIL SOCIETY, AND DONORS THAT MUCH MORE NEEDS TO BE DONE TO BRING HIV/AIDS UNDER CONTROL IN THE REGION. IN NOVEMBER 2017, IT PUBLISHED STIGMA FUELING ASIAN HIV/AIDS EPIDEMICS, AND IN JUNE 2018, IT RELEASED FUNDING GAPS COULD PUT ASIA FURTHER BEHIND ON HIV/AIDS. IN JANUARY 2018, IN COLLABORATION WITH YOUNG PEOPLE LIVING WITH HIV, SOCIAL WORKERS, AND PEDIATRICIANS IN THE ASIA-PACIFIC REGION, TREAT ASIA DEVELOPED TOOLS TO HELP PROVIDERS MANAGE THE TRANSITION OF ADOLESCENTS FROM PEDIATRIC TO ADULT HIV CLINICS. THEY INCLUDE A FLIPCHART FOR USE DURING PROVIDER-PATIENT DISCUSSIONS-AVAILABLE IN ENGLISH, BAHASA INDONESIA, KHMER, MALAY, THAI, AND VIETNAMESE-AND PROVIDE INFORMATION ON DIFFERENCES BETWEEN PEDIATRIC AND ADULT HIV CLINICS, WHEN THE CARE TRANSITION SHOULD BE MADE, WHAT YOUNG PEOPLE SHOULD EXPECT AT AN ADULT HIV CLINIC, AND HIV TREATMENT AND PREVENTION. PRODUCTION WAS SUPPORTED BY THE CHILDREN AND YOUTH PROGRAM OF THE THAI RED CROSS AIDS RESEARCH CENTRE, AND VIIV HEALTHCARES POSITIVE ACTION FOR ADOLESCENTS PROGRAM. IN JUNE 2018, TREAT ASIA PRODUCED A POLICY BRIEF TITLED HEPATITIS C: POLICY RECOMMENDATIONS FOR ADDRESSING A GROWING EPIDEMIC. THE REPORT URGES NATIONAL GOVERNMENTS TO IMPROVE ACCESS TO CARE AND TREATMENT BY ESTABLISHING NATIONAL SURVEILLANCE SYSTEMS AND PROGRAMS FOR VIRAL HEPATITIS, INTEGRATING HIV AND HARM REDUCTION PROGRAMS WITH HEPATITIS C PROGRAMS, BUILDING SKILLS OF NON-SPECIALIST PROVIDERS TO FACILITATE EXPANSION OF HEPATITIS C TREATMENT, AND APPROVING FAST-TRACK REGISTRATION OF DIRECT-ACTING ANTIVIRAL MEDICATIONS THAT ARE EFFECTIVE AGAINST ALL GENOTYPES OF HEPATITIS C.
PROGRAM SERVICE ACCOMPLISHMENTS (3) CONT.	IN ADDITION, TREAT ASIA CONTINUED TO PUBLISH LAY-LANGUAGE ARTICLES ON HIV/AIDS RESEARCH, POLICY, AND COMMUNITY ISSUES FACING THE ASIA-PACIFIC AS A WHOLE. THE ARTICLES AND EDUCATIONAL PIECES APPEAR IN THE TREAT ASIA REPORT, A BIMONTHLY E-NEWSLETTER, AND ON TREAT ASIAS WEBSITE, WWW.TREATASIA.ORG. 17TH ANNUAL NETWORK MEETING THE 2017 TREAT ASIA ANNUAL NETWORK MEETING WAS HELD IN OCTOBER 2017 IN BALI, INDONESIA, WHERE AROUND 100 ADULT AND PEDIATRIC INVESTIGATORS, TREAT ASIA STAFF, AND PROGRAM PARTNERS GATHERED TO REVIEW THE NETWORKS HIV RESEARCH ACCOMPLISHMENTS, COLLECTIVELY PLAN FOR FUTURE INITIATIVES, AND CONSIDER CONTINUED CHALLENGES TO REGIONAL HIV RESEARCH AND RESPONSES. HIGHLIGHTS OF THE 17TH ANNUAL NETWORK MEETING INCLUDED: - PERSPECTIVES ON MOVING FROM CONTROLLING TO ENDING THE HIV EPIDEMICS OF THE ASIA-PACIFIC REGION FROM DR. PRAPHAN PHANUPHAK, DIRECTOR OF THE THAI RED CROSS AIDS RESEARCH CENTRE (TRC-ARC), DRAWING ON HIS MORE THAN THIRTY YEARS OF EXPERIENCE LEADING NATIONAL AND REGIONAL RESEARCH AND RESPONSE EFFORTS. - A DEBATE ON WHETHER HIV SELF-TESTING SHOULD BE AVAILABLE TO ALL ADULTS IN THE REGION, WITH DR. ROSSANA DITANGCO OF THE RESEARCH INSTITUTE FOR TROPICAL MEDICINE, PHILIPPINES, ARGUING IN FAVOR, AND DR. MAN-PO LEE OF QUEEN ELIZABETH HOSPITAL, HONG KONG SAR, CHINA, ARGUING AGAINST. - A PRESENTATION OF THE LATEST RESEARCH ON HIV, AGING, AND MENTAL HEALTH BY DR. REENA RAJASURIAR OF THE UNIVERSITY OF MALAYA, MALAYSIA. - A POLICY PERSPECTIVE ON HOW DATA AND TECHNOLOGY ARE BEING USED TO OPTIMIZE THE IMPACT OF GLOBAL HIV PROGRAMS AND CHARACTERIZE THE SCOPE OF THE OPIOID EPIDEMIC IN THE U.S. BY BRIAN HONERMANN, FROM AMFARS PUBLIC POLICY OFFICE IN WASHINGTON, D.C. OTHER CONFERENCES TREAT ASIA STAFF AND NETWORK INVESTIGATORS ATTENDED AND PRESENTED AT SEVERAL REGIONAL AND INTERNATIONAL CONFERENCES ON HIV-RELATED ISSUES. EXAMPLES INCLUDE: AIDS 2018 IN JULY, TREAT ASIA, PARTNER INVESTIGATORS, AND AFFILIATES PLAYED A PROMINENT ROLE AT THE 22ND INTERNATIONAL AIDS CONFERENCE IN AMSTERDAM, THE NETHERLANDS, LEADING AND PRESENTING AT NUMEROUS PLENARIES, SYMPOSIA, AND OTHER SESSIONS. DR. ANNETTE SOHN, DIRECTOR OF TREAT ASIA, CO-CHAIRED A SYMPOSIUM TITLED "COMING OF AGE WITH HIV: A TESTIMONY OF OUR SUCCESS AND A MEASURE OF OUR READINESS FOR THE FUTURE," AT WHICH DR. THANYAWEE PUTHANAKIT OF CHULALONGKORN UNIVERSITY IN BANGKOK, THAILAND, ALSO SPOKE. DR. WIN MIN HAN OF HIV-NAT, BANGKOK; DR. IVAN MARBANIANG OF BJ GOVERNMENT MEDICAL COLLEGE AND JOHNS HOPKINS UNIVERSITY COLLABORATION IN PUNE, INDIA; AND TARANDEEP ANAND OF ADAM'S LOVE, THAILAND, PRESENTED POSTERS AT THE CONFERENCE. AT THE 10TH INTERNATIONAL WORKSHOP ON HIV PEDIATRICS, WHICH TOOK PLACE IMMEDIATELY BEFORE AIDS 2018, DR. TAVITIYA SUDJARITRUK OF CHIANG MAI UNIVERSITY IN CHIANG MAI, THAILAND; DR. THIDA SINGTOROJ OF TREAT ASIA; AND DR. SUPATTRA RUNGMAITREE OF MAHIDOL UNIVERSITY IN BANGKOK; REPORTED FINDINGS OF A VARIETY OF TREAT ASIA-FUNDED STUDIES ON ASIAN ADOLESCENTS LIVING WITH HIV. ALSO DURING AIDS 2018, DR. SIRINYA TEERAANANCHAI OF THE HIV NETHERLANDS AUSTRALIA THAILAND RESEARCH COLLABORATION (HIV-NAT) BECAME THE FOURTH TREAT ASIA INVESTIGATOR TO RECEIVE A PRESTIGIOUS COLLABORATIVE INITIATIVE FOR PAEDIATRIC HIV EDUCATION AND RESEARCH (CIPHER) GRANT TO STUDY AND DESCRIBE LINKAGE FROM HIV DIAGNOSIS ALONG THE TREATMENT CASCADE IN YOUTH LIVING WITH HIV. APACC TREAT ASIA WAS ALSO WELL REPRESENTED AT THE THIRD ASIA PACIFIC AIDS & CO-INFECTIONS CONFERENCE (APACC) IN JUNE 2018 IN HONG KONG. APACC IS A REGIONAL-LEVEL HIV RESEARCH CONFERENCE THAT PROVIDES OPPORTUNITIES FOR LOCAL CLINICIANS, STUDENTS, AND RESEARCHERS TO SUBMIT ABSTRACTS FOR PRESENTATION. DR. SOHN CO-CHAIRED THE CONFERENCE AND TREAT ASIA RESEARCH DIRECTOR DR. JEREMY ROSS CO-CHAIRED A SESSION ON KEY POPULATION-LED SERVICES. PROGRAM SERVICE ACCOMPLISHMENTS (3) LINE 4C: PUBLIC INFORMATION: AMFAR SEEKS TO TRANSLATE AND DISSEMINATE INFORMATION ON IMPORTANT HIV-RELATED RESEARCH, TREATMENT, PREVENTION, AND POLICY ISSUES FOR DIVERSE AUDIENCES AND TO INCREASE AWARENESS AND KNOWLEDGE OF THE PANDEMIC. AMFAR PUBLISHES A WIDE RANGE OF EDUCATIONAL MATERIALS, MAINTAINS AN INFORMATIVE WEBSITE, AND ENGAGES RESPECTED PUBLIC FIGURES, HIV/AIDS SCIENTISTS, AND POLICYMAKERS IN COMMUNICATING THE NEED FOR CONTINUED RESEARCH TO DEVELOP NEW METHODS OF PREVENTION, TREATMENT, AND, ULTIMATELY, A CURE FOR HIV. EDUCATIONAL MATERIALS AMFAR PRODUCES A RANGE OF PERIODICALS IN BOTH PRINT AND ELECTRONIC FORMATS, INCLUDING ITS NEWSLETTER INNOVATIONS, PUBLISHED TWICE A YEAR AND DISTRIBUTED TO ABOUT 40,000 PEOPLE; THE TREAT ASIA REPORT, AN EMAIL NEWSLETTER DISTRIBUTED SIX TIMES A YEAR TO MORE THAN 4,000 READERS IN THE INTERNATIONAL HEALTH COMMUNITY; AND A MONTHLY E-MAIL NEWSLETTER DISTRIBUTED TO NEARLY 70,000 PEOPLE. THE FOUNDATIONS WEBSITES-WWW.AMFAR.ORG AND WWW.CURECOUNTDOWN.ORG-FEATURE NEWS, INTERVIEWS, AND ORIGINAL ARTICLES COVERING HIV RESEARCH, POLICY, THE GLOBAL EPIDEMIC, AND AMFAR PROGRAMS AND ACTIVITIES. THE WEBSITES ATTRACT A COMBINED AVERAGE OF 45,000 VISITORS PER MONTH. AMFAR ALSO CREATES AND DISTRIBUTES REPORTS, PRESS RELEASES, AND UPDATES ON MAJOR HIV/AIDS ISSUES AND CONDUCTS PUBLIC SERVICE ADVERTISING CAMPAIGNS THAT HAVE BEEN INSTRUMENTAL IN EDUCATING POLICYMAKERS, HEALTHCARE PROFESSIONALS, PEOPLE LIVING WITH HIV/AIDS, AND THE PUBLIC. EPIC VOICES IN FY2018, AMFAR ADDED EIGHT NEW EPIC VOICES TO THE ORIGINAL FOUR POSTED ON CURECOUNTDOWN.ORG. LAUNCHED IN 2017, EPIC VOICES IS AN ONLINE VIDEO SERIES THAT AIMS TO REENERGIZE THE RESPONSE TO HIV AMONG MILLENNIAL AND LGBTQ COMMUNITIES. THE GOALS OF THE CAMPAIGN ARE TO RENEW AWARENESS OF THE PERSISTENT THREAT OF HIV, UNDERSCORE THE URGENT NEED TO ADVANCE HIV RESEARCH, AND SUPPORT AMFARS LEADERSHIP IN THE SEARCH FOR A CURE. ALONG WITH ACTIVISTS AND PEOPLE LIVING WITH HIV, IT FEATURES LEADING RESEARCHERS AND PUBLIC HEALTH PROFESSIONALS. SOCIAL MEDIA AMFAR HAS VIGOROUSLY EXPANDED ITS PRESENCE IN THE SOCIAL MEDIA ARENA, REACHING LARGE NUMBERS OF PEOPLE, INCLUDING A YOUNGER DEMOGRAPHIC THAT IS OFTEN LESS EDUCATED ABOUT HIV AND THE AIDS EPIDEMIC. THE FOUNDATION REGULARLY ADDS CONTENT TO ITS FACEBOOK PAGE, LIVE TWEETS FROM EVENTS, AND POSTS IMAGES ON INSTAGRAM FROM FUNDRAISING AND PROGRAM EVENTS. AMFAR HAS 73,000 LIKES ON FACEBOOK, 43,000 TWITTER FOLLOWERS, AND MORE THAN 155,000 INSTAGRAM FOLLOWERS. MEDIA OUTREACH IN FY2018, AMFAR CONTINUED TO WORK CLOSELY WITH THE MEDIA TO RAISE THE PROFILE OF HIV/AIDS, BOTH DOMESTICALLY AND INTERNATIONALLY, AND TO HELP ENSURE THE ACCURACY OF HIV-RELATED PRESS COVERAGE. ARTICLES AND REPORTS INVOLVING AMFAR-MANY OF WHICH INCLUDED INTERVIEWS WITH STAFF-WERE CARRIED IN NUMEROUS MEDIA OUTLETS, INCLUDING THE LANCET, THE NEW YORK TIMES, THE WASHINGTON POST, THE CHICAGO TRIBUNE, BAY AREA REPORTER, THE ASSOCIATED PRESS, NPR, U.S. NEWS & WORLD REPORT, TIME, THE HILL, DAILY MAIL, CNBC, WABC-TV, CNN, CBS NEWS, NBC NEWS, POLITICO, MEDIA PLANET, BUZZFEED, VOX, KAISER HEALTH NEWS, MODERN HEALTHCARE, HEALTHDAY NEWS, MEDPAGE TODAY, HARPERS BAZAAR, RAI, VOGUE, W MAGAZINE, WWD, POZ, A&U MAGAZINE, INTERNATIONAL BUSINESS TIMES, PAPER, HUFFPOST, AND PEOPLE. CELEBRITY SUPPORT AMFARS PUBLIC AWARENESS EFFORTS ARE GREATLY ENHANCED BY THE COMMITTED SUPPORT OF PUBLIC FIGURES WHO LEND THEIR VOICES AND DONATE THEIR TIME, TALENTS, AND RESOURCES TO HELP SUSTAIN THE FOUNDATIONS MISSION. SUPPORT OF AMFAR BY PROMINENT PUBLIC FIGURES BEGAN WITH THE LATE DAME ELIZABETH TAYLOR, AMFARS FOUNDING INTERNATIONAL CHAIRMAN, AND OTHERS HAVE FOLLOWED IN HER FOOTSTEPS. HEIDI KLUM WAS FEATURED IN AMFARS PUBLIC SERVICE AWARENESS CAMPAIGN ABOUT SAFE SEX, WHICH RESULTED IN COVERAGE FROM BUZZFEED, THEM., CBS NEWS, RAPPLER, NEWNOWNEXT, AND DAILY MAIL. OTHER CELEBRITY SUPPORTERS INCLUDED AMFAR AMBASSADORS MILLA JOVOVICH, MICHELLE YEOH, CHEYENNE JACKSON, AND LIZA MINNELLI, EDWARD ENNINFUL, ZARA LARSSON, JULIAN PERRETTA, ANGELA MISSONI, DEAN AND DAN CATEN, KATE HUDSON, LINDA EVANGELISTA, DONATELLA VERSACE, KATY PERRY, SIENNA MILLER, KAROLINA KURKOVA, BENICIO DEL TORO, STING, GRACE JONES, ELLIE GOULDING, JASON DERULO, NEYMAR JR., SEU JORGE, JEAN-PAUL GAULTIER, KATE MOSS, VIK MUNIZ, KYLIE MINOGUE, TOVE LO, KAWS, CATHY LEE, LEE DANIELS, STEFANO TONCHI, HALSEY, TARAJI P. HENSON, ALAN CUMMING, WHOOPI GOLDBERG, IMAN, SCARLETT JOHANSSON, QUEEN LATIFAH, LAURA LINNEY, JULIA ROBERTS, TOM HANKS, JAMES CORDEN, FERGIE, CHARLIZE THERON, ADRIEN BRODY, JESSICA CHASTAIN, MATT BOMER, GWYNETH PALTROW, DIANA ROSS, CHIARA FERRAGNI, DIANE KRUGER, KATIE HOLMES, UMA THURMAN, ZOE SALDANA, TOBEY MAGUIRE, DAME HELEN MIRREN, LEA MICHELE, MICHELLE RODRIGUEZ, WILL SMITH, NICOLE KIDMAN, NAOMI CAMPBELL, JON HAMM, EVA LONGORIA, NICKI MINAJ, ANDREA BOCELLI, CHRIS TUCKER, JENNIFER GARNER, VICTORIA JUSTICE, AND CARINE ROITFELD.
PROGRAM SERVICE ACCOMPLISHMENTS (5)	LINE 4D: PUBLIC POLICY: INFORMED BY THOROUGH RESEARCH AND ANALYSIS, AMFAR IS A HIGHLY RESPECTED ADVOCATE OF RATIONAL AND COMPASSIONATE HIV/AIDS-RELATED PUBLIC POLICY. THE FOUNDATION IS ENGAGED IN EFFORTS TO SECURE NECESSARY INCREASES IN FUNDING FOR HIV/AIDS RESEARCH; IMPLEMENT THE U.S. NATIONAL HIV/AIDS STRATEGY; EXPAND ACCESS TO CARE AND TREATMENT; ADVOCATE FOR CONTINUED ROBUST U.S. SUPPORT FOR INTERNATIONAL HIV/AIDS PROGRAMS; AND PROTECT THE CIVIL RIGHTS OF ALL PEOPLE AFFECTED BY HIV/AIDS. ENDING THE DOMESTIC HIV EPIDEMIC IN JULY 2018, AMFAR PUBLISHED A SERIES OF REPORTS TO FACILITATE THE ANALYSIS AND POLICY DECISIONS NEEDED TO ADVANCE THE DIFFICULT PROCESS OF DEVELOPING AND DEPLOYING LONG-ACTING HIV TREATMENT AND PREVENTION PRODUCTS CURRENTLY IN THE PIPELINE. LONG-ACTING HIV TREATMENT AND PREVENTION ARE COMING: PREPARING FOR POTENTIAL GAME CHANGERS DESCRIBES THE CRITICAL ISSUES (E.G., FDA REVIEW AND APPROVAL, PAYER COVERAGE, AND ACCESS DECISIONS) THAT MUST BE NAVIGATED BY POLICY MAKERS TO MAKE POTENTIALLY GAME-CHANGING NEW PRODUCTS AVAILABLE FOR PEOPLE LIVING WITH HIV OR VULNERABLE TO INFECTION. HIV AND THE OPIOID EPIDEMIC IN JANUARY 2018, AMFAR PUBLISHED AN ANALYSIS ONLINE IN HEALTH AFFAIRS DETAILING THE AVAILABILITY OF MEDICATION-ASSISTED TREATMENT (MAT) NATIONALLY FOR OPIOID USE DISORDER. WHERE MULTIPLE MODES OF MEDICATION-ASSISTED TREATMENT ARE AVAILABLE ASSESSES ACCESS TO MAT, SPECIFICALLY WHERE DRUG TREATMENT FACILITIES OFFER SEVERAL OF THE THREE CURRENTLY AVAILABLE DRUGS. THESE OPTIONS MAY BE IMPORTANT FOR PATIENTS WITH DIFFERENT TREATMENT NEEDS. THE AUTHORS REPORT THAT IN THE HEART OF APPALACHIA, A REGION HEAVILY AFFECTED BY THE OPIOID EPIDEMIC, KENTUCKY AND TENNESSEE HAVE NO FACILITIES THAT PROVIDE ALL THREE FORMS OF MAT AND ACCEPT MEDICAID. IN MARCH 2018, AMFAR PUBLISHED GETTING TO SERVICES: FAR, FAR AWAY, AN INFOGRAPHIC REVEALING THAT NEARLY 30% OF AMERICANS (95.7 MILLION PEOPLE) LIVE MORE THAN TEN MILES FROM A FACILITY PROVIDING MAT, AND NEARLY 80% (260.9 MILLION PEOPLE) LIVE MORE THAN TEN MILES FROM A SYRINGE SERVICES PROGRAM. SINCE UPTAKE OF TREATMENT FOR SUBSTANCE USE DISORDER AND HARM REDUCTION SERVICES AT SYRINGE SERVICES PROGRAMS CAN REDUCE THE RISK OF ACQUIRING HIV AND HEPATITIS C (HCV) THROUGH THE SHARING OF NEEDLES, ACCESS TO SERVICES IS CRITICALLY IMPORTANT. IN APRIL 2018, AMFAR PUBLISHED A REPORT THAT OUTLINES A COMPREHENSIVE LEGISLATIVE AGENDA TO ADDRESS THE INTERCONNECTED PUBLIC HEALTH THREATS OF OPIOID USE ALONG WITH INFECTIOUS DISEASES SUCH AS HIV AND HCV. TOWARD AN EFFECTIVE STRATEGY TO COMBAT HIV, HEPATITIS C AND THE OPIOID EPIDEMIC: RECOMMENDATIONS FOR POLICY MAKERS PROPOSES A MULTIFACETED STRATEGY THAT INCREASES ACCESS TO TREATMENT, REDUCES THE RISK OF HIV AND HCV ACQUISITION, AND LOWERS THE RISK OF FATAL DRUG OVERDOSES. AMFAR ALSO PUBLISHED AN ANALYSIS ONLINE IN THE AMERICAN JOURNAL OF PUBLIC HEALTH ASSESSING THE IMPACT OF MEDICAID EXPANSION ON THE OPIOID EPIDEMIC. MEDICAID CURRENTLY PROVIDES COVERAGE FOR FOUR IN TEN NON-ELDERLY AMERICANS WITH OPIOID USE DISORDER. WHILE OPIOID PRESCRIBING IN THE MEDICAID POPULATION HAS INCREASED IN RECENT YEARS, THE STUDY FOUND NO STATISTICAL DIFFERENCE IN PRESCRIPTION RATES BETWEEN STATES THAT EXPANDED MEDICAID AND STATES THAT DID NOT, AND THAT AN EXPANSION IN COVERAGE INCREASED ACCESS TO ADDICTION TREATMENT. GLOBAL HEALTH IN MARCH 2018, AMFAR PUBLISHED LIVES ON THE LINE: THE HUMAN IMPACT OF PROPOSED CUTS TO GLOBAL HIV FUNDING, AN INFOGRAPHIC SHOWING THE HUMAN COSTS THAT WOULD RESULT FROM THE TRUMP ADMINISTRATIONS PROPOSED FY2019 BUDGET, INCLUDING $800 MILLION IN PROPOSED CUTS TO THE U.S. PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF (PEPFAR), A 17% DECREASE. SUCH A SUBSTANTIAL DECREASE COULD CAUSE MORE THAN 1 MILLION HIV TREATMENT DISRUPTIONS FOR BOTH CHILDREN AND ADULTS, NEW HIV INFECTIONS, AND HUNDREDS OF THOUSANDS OF PREVENTABLE AIDS-RELATED DEATHS. IN JULY 2018, AMFAR VICE PRESIDENT AND DIRECTOR OF PUBLIC POLICY GREG MILLETT COAUTHORED A LANCET REPORT WARNING THAT UNAIDS TARGETS TO END THE HIV EPIDEMIC BY 2030 CAN ONLY BE MET WITH STRONGER COMBINED HEALTH SERVICE INTEGRATION AND BY INCORPORATING HIV INTO GLOBAL HEALTH POLICY. THIS REPORT ON THE "DANGEROUS COMPLACENCY" THREATENING THE GLOBAL HIV RESPONSE COINCIDED WITH A UNAIDS REPORT WARNING OF NEW HIV INFECTIONS INCREASING IN SOME 50 COUNTRIES, AIDS-RELATED DEATHS NOT FALLING FAST ENOUGH, AND INSUFFICIENT RESOURCES TO SUSTAIN PROGRESS. IN JULY 2018, AMFAR ALSO PUBLISHED AN UPDATED ISSUE BRIEF OUTLINING SERIOUS POTENTIAL IMPACTS OF THE MEXICO CITY POLICY (MCP) ON GLOBAL AIDS FUNDING. MCP HAS HISTORICALLY PROHIBITED U.S. FAMILY PLANNING FUNDING FOR NON-U.S. NONGOVERNMENTAL ORGANIZATIONS PERFORMING OR PROMOTING ABORTION. PRESIDENT REAGAN INTRODUCED THE MEASURE IN 1984 AND IT HAS GONE BACK AND FORTH EVER SINCE. AFTER BEING REPEALED BY PRESIDENT OBAMA, THE POLICY HAS BEEN REVIVED AND EXPANDED BY THE TRUMP ADMINISTRATION. AMFAR FUNDED A STUDY WITH JOHNS HOPKINS UNIVERSITY, GAY SOCIAL NETWORK HORNET, MSM-GF, AND EMORY UNIVERSITY TO COMPARE THE NUMBER OF GAY AND BISEXUAL MEN USING HORNET OR FACEBOOK IN VARIOUS COUNTRIES TO UNAIDS POPULATION SIZE ESTIMATES FOR GAY AND BISEXUAL MEN. IN JULY 2018, AMFAR PUBLISHED WHEN SIZE MATTERS: HOW SOCIAL MEDIA CAN HELP DETERMINE KEY POPULATION SIZE, AN INFOGRAPHIC SHOWING THAT DATA FROM THE STUDY HAD ALREADY BEEN USED TO TRIPLE THE OFFICIAL POPULATION SIZE OF MEN WHO HAVE SEX WITH MEN (MSM) IN TANZANIA. MORE ACCURATE ESTIMATES HELP PEPFAR AND THE GLOBAL FUND SET HIV PREVENTION TARGETS AND BUDGETS THAT ARE SUFFICIENT FOR THE NEEDS OF THESE KEY POPULATIONS. CROI 2018 AMFARS PUBLIC POLICY OFFICE PARTICIPATED IN THE CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI) IN BOSTON IN MARCH. AMFAR POLICY ASSOCIATE ALANA SHARP PRESENTED THE POSTER, "220 VULNERABLE COUNTIES: ONE YEAR LATER," PROVIDING NEW ANALYSIS OF COUNTY-LEVEL ACCESS TO DRUG TREATMENT AND SYRINGE SERVICES FACILITIES NATIONALLY. THE STUDY HIGHLIGHTED SOME PROGRESS IN INCREASING ACCESS TO SERVICES IN VULNERABLE COUNTIES, AND AREAS OF ONGOING CONCERN: COUNTIES THAT ARE VULNERABLE TO HIV AND/OR HEPATITIS C OUTBREAKS HAVE HISTORICALLY HAD LESS ACCESS TO TREATMENT AND HARM REDUCTION SERVICES THAN THE REST OF THE COUNTRY, AND NATIONALLY, ACCESS TO SYRINGE SERVICES REMAINS VERY LOW, WITH LONG AVERAGE DISTANCES TO THESE FACILITIES. IAS 2018 AMFARS PUBLIC POLICY OFFICE PARTICIPATED IN THE 22ND INTERNATIONAL AIDS CONFERENCE (AIDS 2018) IN AMSTERDAM IN JULY. THE OFFICE CO-SPONSORED A SATELLITE SESSION, WITH PLANNED PARENTHOOD GLOBAL AND THE CENTER FOR HEALTH AND GENDER EQUITY, TITLED "THE TRUMP EFFECT: HOW THE U.S. IS JEOPARDIZING THE GLOBAL AIDS RESPONSE." AMFAR ALSO PARTICIPATED IN THE WORKSHOP, "UNDERSTANDING THE GLOBAL GAG RULE: A PRACTICAL WORKSHOP FOR HOW TO SUSTAIN GLOBAL HEALTH PROGRESS AMIDST THE NEW U.S. POLICY ENVIRONMENT." THESE SEMINARS FOCUSED ON THE NUANCES OF POLICY TO HELP IMPLEMENTERS BETTER UNDERSTAND THE POLICY AND EDUCATE ABOUT POTENTIAL HARMS AND HARM REDUCTION STRATEGIES. AMFAR VICE PRESIDENT AND DIRECTOR OF PUBLIC POLICY GREG MILLETT MODERATED "AIDS 2018 LIVE!" A FACEBOOK LIVE SESSION ON HIV FUNDING. AMFAR POLICY ASSOCIATE JENNIFER SHERWOOD PRESENTED A POSTER TITLED "MAPPING THE IMPACT OF THE EXPANDED MEXICO CITY POLICY FOR HIV/FAMILY PLANNING SERVICE INTEGRATION IN PEPFAR-SUPPORTED COUNTRIES: A RISK INDEX.HER COLLEAGUE, POLICY ASSOCIATE ALANA SHARP, PRESENTED THE POSTER: "APPLYING THE GLOBAL FUND ALLOCATION FORMULA-ARE THE DATA DRIVING ALLOCATIONS" IN THE NEWS THROUGHOUT THE YEAR, GREG MILLETT WAS WIDELY QUOTED IN STORIES ON THE OPIOID EPIDEMIC, WHICH OFTEN INCLUDED THE AMFAR OPIOID AND HEALTH INDICATORS DATABASE. MEDIA HIGHLIGHTS INCLUDED BUZZFEED, VOX, REUTERS, AND KAISER HEALTH NEWS. IN OCTOBER 2017, PRESIDENT TRUMP DECLARED THE OPIOID CRISIS A PUBLIC HEALTH EMERGENCY, AND AMFARS PUBLIC POLICY OFFICE WAS INTERVIEWED BY THE MEDIA TO DISCUSS THE IMPACT OF THE OPIOID EPIDEMIC INCLUDING ITS CONNECTION TO DOMESTIC HIV OUTBREAKS. MEDIA HIGHLIGHTS INCLUDED KEY STORIES IN POLITICO AND AN INTERVIEW WITH DR. SUSAN BLUMENTHAL, AMFAR SENIOR POLICY AND MEDICAL ADVISOR, FOR A WASHINGTON POST PODCAST, "CAPE UP." IN OBSERVANCE OF WORLD AIDS DAY IN DECEMBER 2017, AMFAR CEO KEVIN ROBERT FROST WROTE AN OP-ED FOR MEDIAPLANET ON THE DANGERS OF COMPLACENCY AS WELL AS EVOLVING CHALLENGES IN ENDING HIV.
POLICIES	FORM 990, PART VI, SECTION B LINE 11 - THE FORM 990 WAS PREPARED BY A NATIONALLY RENOWNED ACCOUNTING FIRM IN CONJUNCTION WITH THE ORGANIZATION'S FINANCIAL DEPARTMENT. A COPY OF THE DRAFT FORM 990 WAS CIRCULATED TO THE FULL BOARD OF TRUSTEES FOR DISCUSSION AND COMMENT. EACH BOARD MEMBER WAS PROVIDED AMPLE OPPORTUNITY TO COMMENT ON THE INFORMATION CONTAINED IN THE 990 PRIOR TO ITS FILING WITH THE INTERNAL REVENUE SERVICE. LINE 12 - EACH OFFICER, DIRECTOR, TRUSTEE AND KEY EMPLOYEE OF AMFAR ("FOUNDATION") IS REQUIRED TO ANNUALLY DISCLOSE ANY CONFLICTS OF INTEREST THAT ARISE BY VIRTUE OF EMPLOYMENT, BOARD SERVICE, OR POSITION WITH THE FOUNDATION. THE FOUNDATION MONITORS COMPLIANCE WITH ITS CONFLICT OF INTEREST POLICY THROUGH AN ANNUAL QUESTIONNAIRE/DISCLOSURE STATEMENT THAT IS DISTRIBUTED TO THESE INDIVIDUALS. POTENTIAL CONFLICTS ARE INVESTIGATED IMMEDIATELY. LINE 15 - AMFAR ("FOUNDATION FOR AIDS RESEARCH") UNDERTAKES A THOROUGH PROCESS TO ENSURE THAT THE COMPENSATION IT PAYS TO ITS TOP MANAGEMENT OFFICIAL AND ALL OF ITS OFFICERS AND KEY EMPLOYEES IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. AN INDEPENDENT CONSULTING FIRM QUALIFIED IN THE AREA OF NONPROFIT COMPENSATION PREPARES AN ANALYSIS OF MARKET COMPENSATION RANGES BY JOB FUNCTION AND PRESENTS IT TO THE COMPENSATION COMMITTEE OF THE BOARD. ON THE BASIS OF THIS INFORMATION, STAFF COMPENSATION IS DETERMINED ACCORDING TO SALARY RANGES APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD, IN CONSULTATION WITH THE CEO AND CFO. CEO COMPENSATION IS REVIEWED AND DETERMINED BY THE COMPENSATION COMMITTEE OF THE BOARD UTILIZING THE INDEPENDENT CONSULTANT ANALYSIS. AMFAR'S last independent compensation study was commissioned in 2017; the Foundation is in the process of undergoing a compensation study currently to ensure that the President & CEO's compensation is reasonable given the market in which the Foundation operates.
DISCLOSURE	FORM 990, PART VI, SECTION C LINE 19 - AMFAR MAKES ITS FORM 990 AVAILABLE TO THE PUBLIC BY RETAINING A COPY AT ITS PLACE OF BUSINESS AND ON ITS WEBSITE, WWW.AMFAR.ORG. THE FORM 990 IS LIKEWISE PUBLISHED ON THE INTERNET AT WWW.GUIDESTAR.ORG. THE FOUNDATION'S FINANCIAL STATEMENTS ARE MADE AVAILABLE IN ITS ANNUAL REPORT AND ON ITS WEBSITE. THE FOUNDATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE NOT ORDINARILY MADE AVAILABLE TO THE PUBLIC, BUT, IF REQUESTED, WILL BE PROVIDED AT MANAGEMENT'S DISCRETION.
FUNCTIONAL EXPENSES	PART IX, LINES 1 & 3 THE FOUNDATION FOR AIDS RESEARCH REPORTS ITS GRANTS NET OF GRANT RETURNS OR RECOVERIES. PERIODICALLY, GRANTS REMITTED TO CHARITABLE ORGANIZATIONS ARE RETURNED TO AMFAR FOR A VARIETY OF REASONS. ON SCHEDULES F & I, GRANTS ARE REPORTED IRRESPECTIVE OF WHETHER THEY WERE ULTIMATELY RETURNED TO AMFAR SINCE CATEGORIZING THE "RETURNED" AMOUNTS WOULD BE TIME CONSUMING. THEREFORE, AMOUNTS REPORTED ON PART IX, LINE 1 WILL NOT TIE TO TOTAL GRANTS ON SCHEDULE I; AMOUNTS REPORTED ON PART IX, LINE 3 WILL NOT TIE TO TOTAL GRANTS ON SCHEDULE F.